Document:

2004 Outside Directors Stock Option Plan

 Exhibit 10.7 
 SCICLONE PHARMACEUTICALS, INC. 
 2004 OUTSIDE DIRECTORS STOCK OPTION PLAN 
 As Amended Through February 22, 2007 
 1. ESTABLISHMENT, PURPOSE AND TERM OF PLAN. 
 1.1 Establishment. The SciClone Pharmaceuticals, Inc. 2004 Outside Directors Stock Option Plan (the “Plan”) is established effective as of May 26, 2004, the date on
which it is approved by the stockholders of the Company (the “Effective Date”). 
 1.2
Purpose. The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services as Outside Directors of the Company and by
motivating such persons to contribute to the growth and profitability of the Company. 
 1.3 Term of Plan. The Plan shall continue in
effect until terminated by the Board or the date on which all of the shares of Stock available for issuance under the Plan have been issued and all restrictions on such shares under the terms of the Plan and the agreements evidencing Options granted
under the Plan have lapsed. 
 2. DEFINITIONS AND CONSTRUCTION.

 2.1 Definitions. Whenever used herein, the following terms shall have their respective meanings set forth below: 
 (a) “Board” means the Board of Directors of the Company. If one or more Committees have been appointed by the Board
to administer the Plan, “Board” also means such Committee(s). 
 (b)
“Code” means the Internal Revenue Code of 1986, as amended, and any applicable regulations promulgated thereunder. 
 (c) “Committee” means the compensation committee or other committee of one or members of the Board duly appointed to administer the Plan and having such powers as shall be
specified by the Board. Unless the powers of the Committee have been specifically limited, the Committee shall have all of the powers of the Board granted herein, including, without limitation, the power to amend or terminate the Plan at any time,
subject to the terms of the Plan and any applicable limitations imposed by law. 
 (d) “Company” means
SciClone Pharmaceuticals, Inc. a Delaware corporation, or any successor corporation thereto. 
 (e)
“Director” means a member of the Board or of the board of directors of any other Parent Corporation or Subsidiary Corporation. 
  

 1 

 (f) “Disability” means the permanent and total disability of the
Optionee within the meaning of Section 22(e)(3) of the Code. 
 (g) “Exchange Act” means the
Securities Exchange Act of 1934, as amended. 
 (h) “Fair Market Value” means, as of any date, the
value of a share of Stock or other property as determined by the Board, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following: 
 (i) If, on such date, the Stock is listed on a national or regional securities exchange or market system, the Fair Market Value of a share of Stock shall
be the closing price of a share of Stock (or the closing bid price of a share of Stock if the Stock is so quoted instead) as quoted on the Nasdaq National Market, The Nasdaq SmallCap Market or such other national or regional securities exchange or
market system constituting the primary market for the Stock, as reported in The Wall Street Journal or such other source as the Company deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such
securities exchange or market system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded prior to the relevant date, or such other appropriate day as shall be determined by the Board,
in its discretion. 
 (ii) If, on such date, the Stock is not listed on a national or regional securities exchange or market system, the
Fair Market Value of a share of Stock shall be as determined by the Board in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse. 
 (i) “Option” means a right to purchase Stock (subject to adjustment as provided in Section 4.2) pursuant to
the terms and conditions of the Plan. Each Option shall be a nonstatutory stock option; that is, an option not intended to qualify as an incentive stock option within the meaning of Section 422(b) of the Code. 
 (j) “Option Agreement” means a written agreement between the Company and an Optionee setting forth the terms,
conditions and restrictions of the Option granted to the Optionee and any shares acquired upon the exercise thereof. An Option Agreement may consist of a form of “Notice of Grant of Stock Options” and a form of “Stock Option
Agreement” incorporated therein by reference, or such other form or forms as the Board may approve from time to time. 
 (k)
“Optionee” means a person who has been granted one or more Options. 
 (l) “Outside
Director” means a Director who is not an employee of the Company or of any Parent Corporation or Subsidiary Corporation. 
  

 2 

 (m) “Parent Corporation” means any present or future “parent
corporation” of the Company, as defined in Section 424(e) of the Code. 
 (n) “Rule 16b-3”
means Rule 16b-3 under the Exchange Act, as amended from time to time, or any successor rule or regulation. 
 (o)
“Securities Act” means the Securities Act of 1933, as amended. 
 (p)
“Service” means an Optionee’s service with the Company as a Director. An Optionee’s Service shall be deemed to have terminated if the Optionee ceases to be a Director, even if the Optionee continues to
render service to the Company in a capacity other than as a Director or commences rendering service to a Parent Corporation or Subsidiary Corporation. An Optionee’s Service shall not be deemed to have terminated if the Optionee takes any bona
fide leave of absence approved by the Company. Unless otherwise provided by the Board in the grant of an Option and set forth in the Option Agreement evidencing such Option, an approved leave of absence shall be treated as Service for purposes of
determining vesting under the Option. Subject to the foregoing, the Company, in its discretion, shall determine whether the Optionee’s Service has terminated and the effective date of such termination. 
 (q) “Stock” means the common stock of the Company, as adjusted from time to time in accordance with
Section 4.2. 
 (r) “Subsidiary Corporation” means any present or future “subsidiary
corporation” of the Company, as defined in Section 424(f) of the Code. 
 2.2 Construction. Captions and titles contained
herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of
the term “or” is not intended to be exclusive, unless the context clearly requires otherwise. 
 3.
ADMINISTRATION. 
 3.1 Administration by the Board. The Plan shall be administered by the
Board. All questions of interpretation of the Plan or of any Option shall be determined by the Board, and such determinations shall be final and binding upon all persons having an interest in the Plan or such Option. At any time that any class of
equity security of the Company is registered pursuant to Section 12 of the Exchange Act, the Plan shall be administered in compliance with the requirements, if any, of Rule 16b-3. For this purpose, the Board may delegate authority to
administer the Plan to a Committee composed solely of two or more Non-Employee Directors. 
 3.2 Authority of Officers. Any officer of
the Company shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, determination or election which is the responsibility of or which is allocated to the Company herein, provided the officer has
apparent authority with respect to such matter, right, obligation, determination or election. 
  

 3 

 3.3 Indemnification. In addition to such other rights of indemnification as they may have as
members of the Board or officers or employees of the Company, members of the Board and any officers or employees of the Company to whom authority to act for the Board or the Company is delegated shall be indemnified by the Company against all
reasonable expenses, including attorneys’ fees, actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be a party by reason
of any action taken or failure to act under or in connection with the Plan, or any right granted hereunder, and against all amounts paid by them in settlement thereof (provided such settlement is approved by independent legal counsel selected by the
Company) or paid by them in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such person is liable for gross negligence, bad
faith or intentional misconduct in duties; provided, however, that within sixty (60) days after the institution of such action, suit or proceeding, such person shall offer to the Company, in writing, the opportunity at its own expense to handle
and defend the same. 
 4. SHARES SUBJECT TO PLAN.

 4.1 Maximum Number of Shares Issuable. Subject to adjustment as provided in Section 4.2, the maximum aggregate number of shares
of Stock that may be issued under the Plan shall be one million seven hundred sixty-five thousand (1,765,000) and shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof. Shares issuable under the Plan
shall consist of authorized but unissued or reacquired shares of Stock or any combination thereof. If an outstanding Option for any reason expires or is terminated or canceled without having been exercised in full, the shares of Stock allocable to
the unexercised portion of such Option shall again be available for issuance under the Plan. Shares of Stock shall not be deemed to have been issued pursuant to the Plan to the extent such shares are withheld in satisfaction of tax withholding
obligations pursuant to Section 6.5. 
 4.2 Adjustments for Changes in Capital Structure. Subject to any required
action by the stockholders of the Company, in the event of any change in the Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the
stockholders of the Company in a form other than Stock (excepting normal cash dividends) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number and class of
shares subject to the Plan and to any outstanding Options and in the exercise price per share of any outstanding Options in order to prevent dilution or enlargement of Optionees’ rights under the Plan. For purposes of the foregoing, conversion
of any convertible securities of the Company shall not be treated as “effected without receipt of consideration by the Company.” Any fractional share resulting from an adjustment pursuant to this Section 4.2 shall be rounded down to
the nearest 
  

 4 

 whole number, and in no event may the exercise price of any Option be decreased to an amount less than the par value, if
any, of the stock subject to the Option. Such adjustments shall be determined by the Board, and its determination shall be final, binding and conclusive. 
 5. ELIGIBILITY. 
 Options shall be granted only to those persons
who, at the time of grant, are serving as Outside Directors. 
 6. TERMS AND CONDITIONS
OF OPTIONS. 
 Options shall be evidenced by Option Agreements specifying the number of
shares of Stock covered thereby, in such form as the Board shall from time to time establish. Option Agreements may incorporate all or any of the terms of the Plan by reference and shall comply with and be subject to the following terms and
conditions: 
 6.1 Automatic Grant. Subject to the execution by an Outside Director of an appropriate Option Agreement, Options shall
be granted automatically and without further action of the Board, as follows: 
 (a) Initial Option. Each person who first
becomes an Outside Director on or after the Effective Date shall be granted on the date such person first becomes an Outside Director an Option to purchase fifty thousand (50,000) shares of Stock (an “Initial
Option”). 
 (b) Annual Option. Each Outside Director shall be granted on the date of each annual meeting
of the stockholders of the Company which occurs on or after the Effective Date (an “Annual Meeting”) immediately following which such person remains an Outside Director an Option to purchase thirty thousand
(30,000) shares of Stock (an “Annual Option”); provided, however, that an Outside Director granted an Initial Option within the prior one year period immediately preceding the date of an Annual Meeting
shall be granted an option to purchase that number of shares subject to an Annual Option multiplied by a fraction, the numerator of which is the number of full months which have lapsed since the date of appointment as an Outside Director and the
denominator of which is twelve (12). 
 (c) Right to Decline Option. Notwithstanding the foregoing, any person may elect not
to receive an Option by delivering written notice of such election to the Board no later than the day prior to the date such Option would otherwise be granted. A person so declining an Option shall receive no payment or other consideration in lieu
of such declined Option. A person who has declined an Option may revoke such election by delivering written notice of such revocation to the Board no later than the day prior to the date such Option would be granted pursuant to Section 6.1(a)
or (b), as the case may be. 
 6.2 Exercise Price. The exercise price per share of Stock subject to an Option shall be
the Fair Market Value of a share of Stock on the date of grant of the Option. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than 
  

 5 

 the minimum exercise price set forth above if such Option is granted pursuant to an assumption or substitution for
another option in a manner qualifying under the provisions of Section 424(a) of the Code. 
 6.3 Exercisability and Term of
Options. Except as otherwise provided in the Plan or in the Option Agreement evidencing an Option and provided that the Optionee’s Service has not terminated prior to the relevant date, each Option shall vest and become
exercisable as follows: 
 (a) Initial Option. The Initial Option shall vest and become exercisable with respect to one-third
(1/3) of the shares initially subject thereto on the first anniversary of the date of grant, an additional one third (1/3) of the shares initially subject thereto shall vest and become exercisable on the second anniversary of the date of
grant, and the remainder shall vest and become exercisable on the third anniversary of the date of grant. 
 (b) Annual
Option: The Annual Option shall vest and become exercisable with respect to one-twelfth (1/12) of the shares initially subject thereto for each full month of the Optionee’s continuous Service from the date of grant until the Option
is fully vested. 
 (c) Term of Option. Unless earlier terminated in accordance with the terms of the Plan or the Option
Agreement evidencing an Option, each Option shall terminate and cease to be exercisable on the tenth (10th) anniversary of the date of grant of the Option. 
 6.4 Payment of Exercise Price. 
 (a) Forms of Consideration Authorized. Except as
otherwise provided below, payment of the exercise price for the number of shares of Stock being purchased pursuant to any Option shall be made (i) in cash or by check, (ii) by tender to the Company, or attestation to the ownership, of
shares of Stock owned by the Optionee having a Fair Market Value (as determined by the Company without regard to any restrictions on transferability applicable to such stock by reason of federal or state securities laws or agreements with an
underwriter for the Company) not less than the exercise price, (iii) by delivery of a properly executed notice together with irrevocable instructions to a broker providing for the assignment to the Company of the proceeds of a sale or loan with
respect to some or all of the shares being acquired upon the exercise of the Option (including, without limitation, through an exercise complying with the provisions of Regulation T as promulgated from time to time by the Board of Governors of
the Federal Reserve System) (a “Cashless Exercise”), or (iv) by any combination thereof. 
 (b)
Limitations on Forms of Consideration. 
 (i) Tender of Stock. Notwithstanding the foregoing, an Option may not be
exercised by tender to the Company, or attestation to the ownership, of shares of Stock to the extent such tender or attestation would constitute a violation of the provisions of any law, regulation or agreement restricting the redemption of the
Company’s stock. Unless otherwise provided by the 
  

 6 

 Board, an Option may not be exercised by tender to the Company, or attestation to the ownership, of shares of Stock
unless such shares either have been owned by the Optionee for more than six (6) months or were not acquired, directly or indirectly, from the Company. 
 (ii) Cashless Exercise. The Company reserves, at any and all times, the right, in the Company’s sole and absolute discretion, to establish, decline to approve or terminate any program or procedures for the
exercise of Options by means of a Cashless Exercise. 
 6.5 Tax Withholding. The Company shall have the right, but not
the obligation, to deduct from the shares of Stock issuable upon the exercise of an Option, or to accept from the Optionee the tender of, a number of whole shares of Stock having a Fair Market Value, as determined by the Company, equal to all or any
part of the federal, state, local and foreign taxes, if any, required by law to be withheld by the Company with respect to such Option or the shares acquired upon the exercise thereof. Alternatively or in addition, in its discretion, the Company
shall have the right to require the Optionee, by cash payment or otherwise, including by means of a Cashless Exercise, to make adequate provision for any such tax withholding obligations of the Company arising in connection with the Option or the
shares acquired upon the exercise thereof. The Fair Market Value of any shares of Stock withheld or tendered to satisfy any such tax withholding obligations shall not exceed the amount determined by the applicable minimum statutory withholding
rates. The Company shall have no obligation to deliver shares of Stock until the Company’s tax withholding obligations have been satisfied by the Optionee. 
 6.6 Effect of Termination of Service. 
 (a) Option Exercisability. Subject to
earlier termination of the Option as otherwise provided herein, an Option shall be exercisable after an Optionee’s termination of Service only during the applicable time period determined in accordance with this Section 6.6 and thereafter
shall terminate: 
 (i) Disability. If the Optionee’s Service terminates because of the Disability of the Optionee, the Option,
to the extent unexercised and exercisable on the date on which the Optionee’s Service terminated, may be exercised by the Optionee (or the Optionee’s guardian or legal representative) at any time prior to the expiration of twelve
(12) months after the date on which the Optionee’s Service terminated, but in any event no later than the date of expiration of the Option’s term as set forth in the Option Agreement evidencing such Option (the
“Option Expiration Date”). 
 (ii) Death. If the Optionee’s Service terminates because of
the death of the Optionee, the Option, to the extent unexercised and exercisable on the date on which the Optionee’s Service terminated, may be exercised by the Optionee’s legal representative or other person who acquired the right to
exercise the Option by reason of the Optionee’s death at any time prior to the expiration of twelve (12) months after the date on which the Optionee’s Service terminated, but in any event no later than the Option Expiration Date. The
Optionee’s Service shall be deemed to have terminated on account of death if the Optionee dies within three (3) months after the Optionee’s termination of Service. 
  

 7 

 (iii) Other Termination of Service. If the Optionee’s Service terminates for any reason,
except Disability or death, the Option, to the extent unexercised and exercisable by the Optionee on the date on which the Optionee’s Service terminated, may be exercised by the Optionee at any time prior to the expiration of three
(3) months after the date on which the Optionee’s Service terminated, but in any event no later than the Option Expiration Date. 
 (b) Extension if Exercise Prevented by Law. Notwithstanding the foregoing, if the exercise of an Option within the applicable time periods set forth in Section 6.6(a) is prevented by the provisions of
Section 9 below, the Option shall remain exercisable until three (3) months after the date the Optionee is notified by the Company that the Option is exercisable, but in any event no later than the Option Expiration Date. 
 (c) Extension if Optionee Subject to Section 16(b). Notwithstanding the foregoing, if a sale within the applicable time
periods set forth in Section 6.6(a) of shares acquired upon the exercise of the Option would subject the Optionee to suit under Section 16(b) of the Exchange Act, the Option shall remain exercisable until the earliest to occur of
(i) the tenth (10th) day following the date on which a sale of such shares by the Optionee would no longer be subject to such suit, (ii) the one hundred and ninetieth (190th) day after the Optionee’s termination of Service,
or (iii) the Option Expiration Date. 
 6.7 Transferability of Options. During the lifetime of the Optionee, an Option shall be
exercisable only by the Optionee or the Optionee’s guardian or legal representative. No Option shall be assignable or transferable by the Optionee, except by will or by the laws of descent and distribution. Notwithstanding the foregoing, to the
extent permitted by the Board, in its discretion, and set forth in the Option Agreement evidencing such Option, an Option shall be assignable or transferable subject to the applicable limitations, if any, described in the General Instructions to
Form S-8 Registration Statement under the Securities Act. 
 7. STANDARD FORMS OF
OPTION AGREEMENT. 
 7.1 Option Agreement. Each Option shall comply
with and be subject to the terms and conditions set forth in the form of Option Agreement approved by the Board concurrently with its adoption of the Plan and as amended from time to time. 
 7.2 Authority to Vary Terms. The Board shall have the authority from time to time to vary the terms of any standard form of Option
Agreement described in this Section 7 either in connection with the grant or amendment of an individual Option or in connection with the authorization of a new standard form or forms; provided, however, that the terms and conditions of any such
new, revised or amended standard form or forms of Option Agreement are not inconsistent with the terms of the Plan. Such authority shall include, but not by way of limitation, the authority to grant Options which are immediately exercisable subject
to the Company’s right to repurchase any unvested shares of Stock acquired by the Optionee on exercise of an Option in the event such Optionee’s Service is terminated for any reason. 
  

 8 

 8. EFFECT OF CHANGE IN
CONTROL. 
 8.1 Definitions. 
 (a) An “Ownership Change Event” shall be deemed to have occurred if any of the following occurs with respect to the
Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation
in which the Company is a party; (iii) the sale, exchange, or transfer of all or substantially all of the assets of the Company; or (iv) a liquidation or dissolution of the Company. 
 (b) A “Change in Control” shall mean an Ownership Change Event or a series of related Ownership Change Events
(collectively, a “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain immediately after the Transaction, in substantially the same proportions as their
ownership of shares of the Company’s voting stock immediately before the Transaction, direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of the outstanding voting securities of the
Company or, in the case of a Transaction described in Section 8.1(a)(iii), the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as the case may
be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company
or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. The Board shall have the right to determine whether multiple sales or exchanges of the voting securities of the Company
or multiple Ownership Change Events are related, and its determination shall be final, binding and conclusive. 
 8.2 Effect of Change in
Control on Options. In the event of a Change in Control, any unexercisable or unvested portions of outstanding Options and any shares acquired upon the exercise thereof shall be immediately exercisable and vested in full as of the date ten
(10) days prior to the date of the Change in Control. The exercise or vesting of any Option and any shares acquired upon the exercise thereof that was permissible solely by reason of this Section 8.2 shall be conditioned upon the
consummation of the Change in Control. In addition, the surviving, continuing, successor, or purchasing corporation or parent corporation thereof, as the case may be (the “Acquiror”), may either assume the
Company’s rights and obligations under outstanding Options or substitute for outstanding Options substantially equivalent options for the Acquiror’s stock. Any Options which are neither assumed or substituted for by the Acquiror in
connection with the Change in Control nor exercised as of the date of the Change in Control shall terminate and cease to be outstanding effective as of the date of the Change in Control. Notwithstanding the foregoing, if the corporation the stock of
which is subject to the outstanding Options immediately prior to an Ownership Change Event described in Section 8.1(a)(i) constituting a Change in Control is the surviving or continuing corporation and immediately after such Ownership Change
Event less than 
  

 9 

 fifty percent (50%) of the total combined voting power of its voting stock is held by another corporation, the
outstanding Options shall not terminate unless the Board otherwise provides in its discretion. For the purposes of this Section 8.2, an Option shall be considered assumed if, for every share of Stock subject thereto immediately prior to the
Change in Control, the Optionee has the right, following the Change in Control, to acquire in accordance with the terms and conditions of the assumed Option the consideration (whether stock, cash or other securities or property) received in the
Change in Control transaction by holders of shares of Stock for each share held immediately prior to such transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the
outstanding shares of Stock); provided, however, that if such consideration received in the Change in Control transaction was not solely common stock of the Acquiror, the Board may, with the consent of the Acquiror, provide for the consideration to
be acquired to be solely common stock of the Acquiror equal in Fair Market Value to the per share consideration received by holders of Stock in the Change in Control transaction. 
 9. COMPLIANCE WITH SECURITIES LAW. 
 The grant of Options and the issuance of shares of Stock upon exercise of Options shall be subject to compliance with all applicable requirements of
federal, state and foreign law with respect to such securities. Options may not be exercised if the issuance of shares of Stock upon exercise would constitute a violation of any applicable federal, state or foreign securities laws or other law or
regulations or the requirements of any stock exchange or market system upon which the Stock may then be listed. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s
legal counsel to be necessary to the lawful issuance and sale of any shares hereunder shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority shall not have been
obtained. As a condition to the exercise of any Option, the Company may require the Optionee to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any
representation or warranty with respect thereto as may be requested by the Company. 
 10. TERMINATION OR
AMENDMENT OF PLAN. 
 The Board may terminate or amend the Plan at any
time. However, without the approval of the Company’s stockholders, there shall be (a) no increase in the maximum aggregate number of shares of Stock that may be issued under the Plan (except by operation of the provisions of
Section 4.2), (b) no material change in the class of persons eligible to receive Options, and (c) no material change in the amount, timing or exercise price formula of automatic grants of Options pursuant to Section 6.1 above. No
termination or amendment of the Plan shall affect any then outstanding Option unless expressly provided by the Board. In any event, no termination or amendment of the Plan may adversely affect any then outstanding Option without the consent of the
Optionee. 
  

 10 

 11. MISCELLANEOUS PROVISIONS. 
 11.1 Provision of Information. Each Optionee shall be given access to information concerning the Company equivalent to that information generally
made available to the Company’s common stockholders. 
 11.2 Fractional Shares. The Company shall not be required to issue
fractional shares upon the exercise of any Option. 
 11.3 Beneficiary Designation. Each Optionee may file with the Company a written
designation of a beneficiary who is to receive any benefit under the Plan to which the Optionee is entitled in the event of such Optionee’s death before he or she receives any or all of such benefit. Each designation will revoke all prior
designations by the same Optionee, shall be in a form prescribed by the Company, and will be effective only when filed by the Optionee in writing with the Company during the Optionee’s lifetime. If a married Optionee designates a beneficiary
other than the Optionee’s spouse, the effectiveness of such designation shall be subject to the consent of the Optionee’s spouse. 
 11.4 Rights as a Stockholder. An Optionee shall have no rights as a stockholder with respect to any shares covered by an Option until the date of the issuance of a certificate for such shares (as evidenced by the appropriate entry on
the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date such certificate is issued, except as provided
in Section 4.2 or another provision of the Plan. 
  

 11Assignment and Purchase Agreement

 EXHIBIT 10.17 
 CONFIDENTIAL PROVISIONS REDACTED 
 ASSIGNMENT AND PURCHASE AGREEMENT 
 THIS ASSIGNMENT AND PURCHASE AGREEMENT (the “Agreement”) is entered into this 25th day of April, 2007 (the “Effective
Date”) by and among Resistys, Inc., a Delaware corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Resistys”), Avantogen Limited (formerly, Australian
Cancer Technology Limited), an Australian corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Avantogen”), Avantogen Oncology, Inc. (formerly, Innovate
Oncology, Inc.), a Nevada corporation having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“AOI”), and SciClone Pharmaceuticals, Inc. a Delaware corporation, having its
principal place of business at 901 Mariners Island Blvd., San Mateo, California 94404 (“Buyer”) (Resistys, Avantogen and AOI also referred to herein individually and collectively as, “Seller”). 
 RECITALS 
 A. Avantogen formed Resistys in
August 2004 as a wholly-owned subsidiary. 
 B. Resistys, Avantogen and RESprotect GmbH, a German corporation having an office at Fiedlerstr.
34, D-01307 Dresden, Germany (“Licensor”), entered into that certain License Agreement dated August 30, 2004 (the “License Agreement”), pursuant to which, among other things, (1) RESprotect granted
Resistys an exclusive license to develop and commercialize certain pharmaceutical products in the United States and Canada under certain intellectual property rights of RESprotect related to RP101 ((E)-5-(2- bromovinyl-)2’-deoxyuridine - also
known as BVDU) (“RP101”), and (2) Avantogen guaranteed the payment of Resistys’ royalty and other financial obligations to RESprotect under the License Agreement. 
 C. In connection with the License Agreement, Resistys and RESprotect entered into that certain Supply Agreement for Clinical Trial Material dated
September 13, 2004 (the “Supply Agreement”), pursuant to which, among other things, RESprotect agreed to supply Resistys with tablets containing RP101 for use by Resistys in conducting certain clinical trials related to RP101.

 D. In October 2004, Bioaccelerate Holdings, Inc. (now known as Gardant Pharmaceuticals, Inc.) (“Gardant”), AOI’s then
parent, entered into an agreement with Avantogen pursuant to which Gardant acquired a 50% shareholder interest in Resistys and agreed to provide 50% of the funding for the development of RP101. 
  

 CONFIDENTIAL TREATMENT 

 E. In March 2006, AOI became the holder of Gardant’s 50% shareholder interest in Resistys.

 F. In May 2006, Avantogen and Gardant entered into an agreement pursuant to which Avantogen transferred its 50% shareholder interest in
Resistys to AOI in exchange for a majority shareholder interest in AOI (54.2%) and Resistys became the wholly-owned subsidiary of AOI. In connection with these transactions, AOI changed its name from Innovate Oncology, Inc. to Avantogen
Oncology, Inc. 
 G. Buyer desires to purchase, and Seller desires to sell to Buyer, certain assets owned or controlled by Seller related to
Seller’s program to develop and commercialize RP101 under the License Agreement (the “RP101 Program”), on the terms and subject to conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the agreements of the parties hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS AND INTERPRETATIONS 
 1.1 Definitions. When used in this Agreement, the following capitalized terms shall have the meanings set forth below, and any other capitalized
term used herein shall have the meaning set forth in the particular provision of this Agreement in which it is first defined. 
 (a)
“Additional Payment Term” means the period commencing on the Effective Date and ending on the earlier to occur of (i) [****], or (ii) [****]. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 (b) “Affiliate” shall mean any entity that controls, is controlled by, or is under
common control with a party. An entity shall be regarded as in “control” of another entity if it owns, or directly or indirectly controls, more than [****] of the voting stock or other ownership interest of the other entity, or if
it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the entity or the power to elect or appoint [****] or more of the members of the governing body of the entity. 
 (c) “Agreement” shall have the meaning given in the opening paragraph of this Agreement. 
 (d) “AOI” shall have the meaning given in the opening paragraph of this Agreement. 
 (e) “Asset Transfer and Assumption Agreements” shall have the meaning given in the first paragraph of Article 2. 
 (f) “Assumed Agreements” shall have the meaning given in Section 2.1(a). 
 (g) “Assumed Liabilities” shall have the meaning given in Section 3.1. 
 (h) “Avantogen” shall have the meaning given in the opening paragraph of this Agreement. 
 (i) “Books and Records” shall have the meaning given in Section 2.1(f). 
 (j) “Buyer” shall have the meaning given in the opening paragraph of this Agreement. 
 (k) “Buyer Indemnitee(s)” shall have the meaning given in Section 8.4. 
 (l) “Buyout Consideration” shall have the meaning given in Section 7.8. 
 (m) “Buyout Date” shall have the meaning given in Section 7.8. 
 (n) “Buyout Notice” shall have the meaning given in Section 7.8. 
 (o) “Buyout Period” shall have the meaning given in Section 7.8. 
 (p) “Buyout Right” shall have the meaning given in Section 7.8. 
 (q) “Claim” shall have the meaning given in Section 8.5. 
 (r) “Closing” shall have the meaning given in Section 7.1. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 (s) “Collateral” shall have the meaning given in Section 4.5. 
 (t) “Common Stock” shall mean Buyer’s common stock, par value $0.001 per share. 
 (u) “Confidential Information” shall mean all confidential and proprietary information provided by one party to the other party pursuant
to this Agreement, or generated pursuant to this Agreement, except any portion thereof which: (i) the recipient can demonstrate by its written records was rightfully known by the recipient prior to the disclosure thereof by the disclosing
party; (ii) is disclosed to the recipient without restriction, after disclosure thereof by the disclosing party, by a third party who has the right to make such disclosure; or (iii) is or becomes part of the public domain through no breach
of this Agreement by the recipient. 
 (v) “Creditors” shall have the meaning given in Section 5.3. 
 (w) “Disclosure Schedule” shall mean the Disclosure Schedule of Seller attached hereto as Schedule 5. 
 (x) “Effective Date” shall have the meaning given in the opening paragraph of this Agreement. 
 (y) “Escrow Agent” shall have the meaning given in Section 4.1. 
 (z) “Escrow Agreement” shall have the meaning given in Section 4.1. 
 (aa) “Escrow Period” shall have the meaning given in Section 4.1. 
 (bb) “Excluded Liabilities” shall have the meaning given in Section 3.2. 
 (cc) “FDA” shall mean the United States Food and Drug Administration or any successor agency thereof. 
 (dd) “First Commercial Sale” shall mean the first sale of RP101 Product by Buyer, an Affiliate thereof, and/or its Sublicensees.

 (ee) “Liabilities” shall mean any debt, obligation, duty or liability of any nature whatsoever (including any unknown,
undisclosed, unmatured, unaccrued, unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether such debt, obligation, duty or liability would be required to be
disclosed on a balance sheet prepared in accordance with generally accepted accounting principles and regardless of whether such debt, obligation, duty or liability is immediately due and payable. 
 (ff) “License Agreement” shall have the meaning given in Recital B. 
 (gg) “Licensor” shall have the meaning given in Recital B. 
  

 CONFIDENTIAL TREATMENT 

 (hh) “Manufacturing Information” shall mean all documents, materials, data, know-how and
other information owned by Seller, or in which Seller has rights, related to producing, manufacturing, labeling, packaging, storing, handling, testing (including stability and quality control testing) and release of RP101, existing as of the date
hereof, including specifications and manufacturing and quality control instructions or requirements under any quality control agreements, and any and all other written or electronic information related thereto. 
 (ii) “Market Sales” means the gross amount invoiced for the sale of RP101 Product in the Territory by Buyer, its Affiliates and
Sublicensees, less any amounts invoiced to customers for customs duties or sales taxes directly related to the sale of the RP101 Product, or for transportation, shipping and insurance costs. 
 (jj) “NDA” means a means a New Drug Application filed with the FDA. 
 (kk) “Net Sales” means the gross invoiced sales price of RP101 Product in the Territory by Buyer, its Affiliates and Sublicensees, less
[****]. 
 (ll) “Patent Rights” shall mean the rights under any patent applications, issued patents and any and all
substitutions, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations. 
 (mm) “Phase II Clinical
Trial” shall mean a phase II clinical trial as defined in 21 C.F.R. 312.21(b), as amended from time to time. 
 (nn) “Phase
III Clinical Trial” shall mean a phase III clinical trial as defined in 21 C.F.R. 312.21(c), as amended from time to time. 
 (oo)
“PRA” shall mean Pharmaceutical Research Associates, Inc. 
 (pp) “PRA Agreement” shall mean that certain
Agreement for Clinical Trials Management Services dated as of August 31, 2006 by and between AOI and PRA (PRA Project ID: [****]). 
 (qq) “Purchase Price” shall have the meaning given in Section 4.1. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 (rr) “Regulatory Filings” shall mean (i) all notices, submissions, applications and
other regulatory filings filed or otherwise submitted to the FDA or any other U.S. or foreign regulatory agency with similar responsibilities to the FDA (individually and collectively, a “Regulatory Authority”), (ii) all
permits, licenses, registrations and other approvals or authorizations issued or otherwise granted by a Regulatory Authority, and (iii) all correspondence related thereto, with respect to RP 101 or the RP101 Program, including investigational
new drug applications and approvals to conduct clinical trials. 
 (ss) “Research and Development Materials” shall mean all
research and development information owned by Seller, or in which Seller has rights, related to the RP101 Program or the RP101 Assets, including clinical and non-clinical data, lab notebooks and reports, existing as of the date hereof, and any and
all other written or electronic information related thereto. 
 (tt) “RESprotect Invoices” shall have the meaning given in
Section 3.1. 
 (uu) “RESprotect Know-How Rights” means any of Licensor’s confidential proprietary information and
materials relating to the research, development, manufacture, approval, marketing, use or sale of RP101 which during the term of the License Agreement are or prior to the License Agreement were developed by Licensor and which Licensor is permitted
to disclose to Resistys without violating any third party agreements. 
 (vv) “RESprotect Patent Rights” means any Patent
Rights under U.S. Patent No. 6,589,941, a patent or patents issuing on U.S. patent application published as 20040127454 only to the extent they relate to RP 101 and any U.S. and/ or Canadian patents or patent applications claiming priority to,
or directly related to, the foregoing patents or patent applications filed by Licensor only to the extent they relate to RP 101. 
 (ww)
“Returns” shall have the meaning given in Section 5.11. 
 (xx) “RP101 Assets” shall have the meaning
given in Section 2.1. 
 (yy) 
 (zz) “RP101 IND” means Investigational New Drug Application (IND) [****] of AOI, approved by the FDA on October 30, 2006. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 (aaa) 
 (bbb) “RP101 Product” means RP101 ((E)-5-(2- bromovinyl-)2’-deoxyuridine - also known as BVDU), a salt of BVDU or a prodrug of BDVU (if developed by Licensor) for use under the RESprotect Patent
Rights, (a) which incorporates, embodies, utilizes or is based on RESprotect Know-How Rights, or (b) the manufacture, use, importation or sale of which would, but for the rights granted hereunder, constitute infringement of a Valid Claim
under the RESprotect Patent Rights. 
 (ccc) “RP101 Program” shall have the meaning given in Recital G. 
 (ddd) “Securities Act” shall mean the Securities Act of 1933, as amended. 
 (eee) “Security Agreement” shall have the meaning given in Section 4.5. 
 (fff) “Seller” shall have the meaning given in the opening paragraph of this Agreement. 
 (ggg) “Seller Indemnities” shall have the meaning given in Section 8.3. 
 (hhh) “Seller IP Rights” shall mean all intellectual property made, developed, reduced to practice or licensed or otherwise acquired and
controlled by Seller in the course of or in connection with the RP101 Program or relating to the RP101 Assets (other than the RESprotect Patent Rights and RESprotect Know-How Rights themselves, but including any improvements or enhancements
thereto), including all tangible and intangible information, know-how, methods, procedures, processes, formulations, technical information, trade secrets, inventions, specifications, instructions, formulae, expertise, and biological, chemical,
pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical, clinical, and other data and information, improvements and enhancements, the Manufacturing Information and the
Research and Development Materials, whether or not patentable, and any patent, patent applications, or other intellectual property rights based on the foregoing. 
 (iii) “Sublicensee” shall mean any party who receives a sublicense from Buyer relating to the License Agreement upon entering into any of the following agreements with Buyer: (i) a sublicense
agreement, (ii) research and development agreement, or (iii) alternative form of collaboration or commercialization agreement, such as, but not limited to, a co-promotion or co-marketing arrangement to research, develop, import, make, use,
offer for sale, and/or sell RP101 Product in the Territory. 
  

 CONFIDENTIAL TREATMENT 

 (jjj) “Supply Agreement” shall have the meaning given in Recital C. 
 (kkk) “Tax” and “Taxes” shall mean all present or future taxes, charges, fees, levies, or other assessments including,
without limitation, income, excise, property, value added, real estate, sales, payroll, transfer, social security and franchise taxes imposed by any federal, state, county, or local government, or a subdivision or agency thereof. Such term shall
include any interest, penalties, or additions payable in connection with such taxes, charges, fees, levies, duties, or other assessments. 
 (lll) “Territory” means the United States of America and Canada. 
 (mmm) “Valid Claim” shall mean
a claim of an issued and unexpired patent within the RESprotect Patent Rights, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 
 1.2 Interpretation. In this Agreement, words importing the singular number only shall include the plural and vice versa, words importing a specific gender shall include the other genders and references to
persons shall include their heirs, executors, administrators or assigns, as the case may be. As used in this Agreement, “including” means “including, without limitation,”, and “herein”, “hereof”, and
“hereunder” refer to this Agreement as a whole. Unless otherwise expressly provided herein, any reference to a number of “days” hereunder shall refer to calendar days. All references to “Dollars” stated in this
Agreement are to U.S. dollars. 
 ARTICLE 2 
 TRANSFER OF RP101 ASSETS 
 Subject to the terms and conditions of this Agreement, at Closing Seller
shall sell, transfer, assign, convey and deliver to Buyer all of their respective right, title and interest in and to the RP101 Assets, and Buyer shall assume all of the rights, obligations and responsibilities associated therewith, including all
claims, causes of action, rights of recovery and rights of set off of any kind, as stated in this Agreement. The sale, transfer, assignment, conveyance and delivery of the RP101 Assets to Buyer will be effected by Seller pursuant to such good and
sufficient instruments of conveyance, transfer and assignment, as determined by Buyer in its reasonable discretion (the “Asset Transfer and Assumption Agreements”), as shall be necessary or advisable to transfer to Buyer good and
valid title to the RP101 Assets. Seller shall execute 
  

 CONFIDENTIAL TREATMENT 

 on or prior to the Effective Date, the Asset Transfer and Assumption Agreements and such bills of sale and other
instruments, documents and agreements as may be necessary to effect the transactions contemplated by this Agreement. 
 2.1 RP101
Assets. The following assets related to the RP101 Program shall constitute the RP101 Assets: 
 (a) the agreements listed on Schedule
2.1(a) hereto (the “Assumed Agreements”); 
 (b) all Seller IP Rights, including the Seller IP Rights set forth on
Schedule 2.1(b); 
 (c) all Regulatory Filings set forth on Schedule 2.1(c); 
 (d) all Manufacturing Information, including the Manufacturing Information set forth on Schedule 2.1(d); 
 (e) all Research and Development Materials, including the Research and Development Materials set forth on Schedule 2.1(e); 
 (f) all books, files, papers, correspondence, databases, software, documents and records relating to the RP101 Assets or the Assumed Liabilities, on
whatever medium (“Books and Records”). 
 2.2 Third Party Consents. At Closing, Seller shall obtain and deliver to
Buyer, at Seller’s sole cost and expense, any and all required consents to the sale, transfer, assignment, conveyance and delivery of the RP101 Assets, in form and substance reasonably acceptable to Buyer. 
 2.3 Transfer Taxes. All applicable sales, transfer, documentary, use, filing, recording and other taxes and fees that may be levied on the sale,
assignment, transfer or delivery of the RP101 Assets to be sold and transferred as provided herein based on the Purchase Price, if any, shall be borne equally by Seller and Buyer, and all other applicable sales, transfer, documentary, use, filing,
recording and other taxes and fees shall be borne solely by Seller. 
 ARTICLE 3 
 ASSUMED LIABILITIES 
 3.1 Assumed
Liabilities. Subject to the terms and conditions of this Agreement, at Closing Seller shall assign, and Buyer shall assume, the Liabilities of Seller under the Assumed Agreements arising after the Effective Date (the “Assumed
Liabilities”). 
  

 CONFIDENTIAL TREATMENT 

 The parties acknowledge that the Assumed Liabilities include Three Hundred Sixty-Five Thousand Four Hundred Seventy-Four
United States Dollars (US$365,474) owed by Resistys to Licensor under the Supply Agreement (Invoice Nos. 07/2006 and 08/2006) for certain RP101 product ordered, but not delivered to Seller (the “RESprotect Invoices”), which invoices
shall be paid by Buyer at Closing. 
 3.2 Excluded Liabilities. Except for the Assumed Liabilities, Buyer shall not assume and shall
not be liable or responsible for, and Seller shall retain, and as between (a) Buyer and (b) Seller, remain solely liable for and obligated to discharge, all other Liabilities of Seller, including Liabilities related or attributable to the
RP101 Assets or the RP101 Program arising prior to the Effective Date (the “Excluded Liabilities”). 
 ARTICLE 4

 CONSIDERATION 
 4.1
Purchase Price; Escrow. As full consideration for the sale, purchase, assignment, transfer and delivery of the RP101 Assets as contemplated hereby, at Closing Buyer shall pay to Resistys cash in the aggregate amount of One Million Six Hundred
Eighty Thousand Dollars ($1,680,000) (the “Purchase Price”). The Buyer and Seller agree that, at Closing, Buyer shall pay the Purchase Price as follows: (a) (i) Forty Nine Thousand Seven Hundred Sixty One Dollars and Forty
Eight Cents ($49,761.48) shall be paid to Licensor on behalf of Seller in payment of the amount owed to RESprotect as indicated on Schedule 5.3, and (i) One Hundred Thirteen Thousand Five Hundred Eighty Nine Dollars and Sixty Three Cents
($113,589.63) shall be paid to PRA on behalf of Seller in payment of the amount owed to PRA as indicated on Schedule 5.3, (the “Direct Payments”), and (b) One Million Five Hundred Sixteen Thousand Six Hundred Forty Eight
Dollars and Eighty Nine Cents ($1,516,648.89) (the “Purchase Price Balance”) shall be paid to Katten Muchin Rosenman LLP (the “Escrow Agent”), who shall hold the Purchase Price Balance in escrow pursuant to the
Escrow Agreement attached hereto as Exhibit 4.1 (the “Escrow Agreement”). As provided in the Escrow Agreement, at Closing the Escrow Agent shall use the Purchase Price Balance to pay the amounts owed to the Creditors as set
forth in Schedule 5.3 of the Disclosure Schedule (except the Direct Payments, which shall be paid by Buyer as set forth above in this paragraph), and shall hold the balance remaining after making such payments in escrow for a period of thirty
(30) days (the “Escrow Period”). 
  

 CONFIDENTIAL TREATMENT 

 During the Escrow Period, if Buyer, Seller or Escrow Agent becomes aware of the existence of any other creditors of
Seller or additional claims of existing Creditors, they shall promptly inform the other parties. If after consultation among Buyer and Seller, the parties agree as to the validity of any such claims, Buyer and Seller shall instruct the Escrow Agent
to pay such claims out of the remaining balance of the Purchase Price Balance. Upon the expiration of the Escrow Period, any remaining balance less any amounts equal to any pending unresolved claims shall be distributed to Resistys. 
 4.2 Milestone Payments. During the Additional Payment Term, Buyer shall also make the following one-time milestone payments to Resistys in
accordance with Section 4.4, as and only to the extent that they become due and payable hereunder (the “Milestone Payments”): 
 (a) [****]; 
 (b) [****]. For purposes of this Agreement, “FDA approval” shall mean the receipt of approval
from the FDA under the Prescription Drug User Fee Act (PDUFA) for the RP101 Product in the United States; 
 (c) [****]; 

(d) [****]; 
 (e) [****];
and 
 (f) [****]. 
 4.3
Net Sales Payments. During the Additional Payment Term and subject to Section 7.8, Buyer shall also make the following payments to Resistys in accordance with Section 4.4, as and only to the extent that they become due and payable
hereunder (the “Net Sales Payments”): 
 (a) [****], and 
 (b) [****]. 
 Example: [****]

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 4.4 Payment of Milestone and Net Sales Payment. 
 (a) Method of Payment. The payments to be made pursuant to Sections 4.2 and 4.3 shall be made when due and payable in U.S. dollars by wire
transfer in immediately available funds to such account as Resistys shall have designated to Buyer in writing, and any such payment shall be deemed to have been paid when recorded in the proper account. 
 (b) Payment of Milestone Payments. Buyer shall pay Resistys the Milestone Payment in the amount, and within thirty (30) days of the
occurrence, of the applicable Milestone Event. 
 (c) Reports and Payments of Net Sale Payments. Within sixty (60) days after the
close of each calendar quarter after the First Commercial Sale of RP101 Product by Buyer, its Affiliates or its Sublicensees to third parties in the Territory, Buyer shall deliver to Resistys a report showing (i) the Net Sales of the RP101
Product during the reporting period, (ii) the payment due thereon pursuant to Section 4.3; and (iii) withholding and other taxes, if any, required by law to be deducted in respect of such payments. If no payment is due under
Section 4.3 for any quarterly period, Buyer shall so report. Buyer shall keep complete and accurate records in sufficient detail to properly reflect all Net Sales and to enable the amounts payable pursuant to Section 4.3 to be determined.

 (d) Exchange Rates. For purposes of calculating the amounts payable Resistys pursuant to Section 4.2 or 4.3, Net Sales in
Canadian dollars shall be converted into U.S. dollars using the arithmetic average of the spot rates on the last business day of each month of the calendar quarter in which the Net Sales were made. The “closing mid-point rates” found in
the “dollar spot forward against the dollar” table published by The Wall Street Journal or any other publication as agreed to by the parties shall be used as the source of spot rates to calculate the average as defined in the preceding
sentence. 
 (e) Prohibitions on Remittances. If at any time legal restrictions in any country in the Territory prevent the prompt
remittance of any payments due with respect to Net Sales in that country, Buyer shall have the right and option to make such payments by depositing the amount thereof in local currency to a Resistys account in a bank or depository in such country
designated by Resistys. 
 (f) Tax Matters. Any withholding or other taxes which Buyer is required by law to pay or withhold on behalf
of Resistys with respect to any payments required to be made hereunder shall be deducted from the amount of such payments due, and 
  

 CONFIDENTIAL TREATMENT 

 promptly paid or remitted as appropriate, by Buyer on behalf of Resistys. Any such tax required by law to be paid or
withheld shall be an expense of, and borne solely by, Resistys. Buyer shall furnish Resistys with evidence of such payment or amount withheld as soon as practicable after such payment is made or such amount is withheld. Buyer and Resistys shall use
commercially reasonable efforts to minimize any such taxes required to be paid or withheld by Buyer on behalf of Resistys. Without limitation of the foregoing, the parties will reasonably co-operate in completing and filing documents required under
the provisions of any applicable tax laws or any other applicable law in connection with the making of any required tax payment or withholding payment, in connection with a claim of exemption from, or entitlement to, a reduced rate of withholding or
in connection with any claim to a refund of or credit for any such payment. 
 (g) Audits. Upon written request and advance notice of
not less than thirty (30) days, Buyer shall permit an internal auditor or independent public accountant selected by Resistys and acceptable to Buyer, which acceptance shall not be unreasonably withheld or delayed, to have access during normal
business hours to such records of Buyer as may be reasonably necessary to verify the accuracy of the reports described in Section 4.4(c), in respect of any calendar year ending not more than three (3) calendar years prior to the date of
such request. All such verifications shall be conducted at Resistys’ expense and not more than once in any calendar year. If, after consultation with Buyer, such Resistys representative concludes, providing sufficient evidence, that additional
amounts were owed to Resistys during such period pursuant to Section 4.3, the additional amount shall be paid by Buyer within thirty (30) days of the date Resistys delivers to Buyer such representative’s written report so concluding.
The fees and expenses charged by such representative shall be paid by Resistys unless the audit discloses that the amounts payable by Buyer for the audited period are underpaid by more than five percent (5%), in which case Buyer shall pay the
reasonable fees and expenses charged by such representative as well as the amount of such underpayment. Any overpayment will be refundable or credited against future payments hereunder. Buyer shall include in each sublicense of the RESprotect Patent
Rights a provision requiring the sublicensee to make reports to Buyer, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by Resistys’ representatives to the same extent required of Buyer
under this Agreement. Resistys agrees that all information subject to review under this Section 4.5(g) or under any sublicense agreement will be Confidential Information and that Resistys will cause its representatives to retain all such
information in confidence. 
  

 CONFIDENTIAL TREATMENT 

 (h) Late Payments. If any payments owed by Buyer to Resistys under Sections 4.2 or 4.3 are not
paid when due and payable, Resistys will have the right to charge interest on the past due amounts at a rate equal to two (2) percentage points over the one (1) year LIBOR rate applicable at the time the payment is due. 
 (i) Termination. For the avoidance of doubt, Buyer’s obligation to make the Milestone Payments and the Net Sales Payments shall terminate
upon the expiration of the Additional Payment Term, provided that if Buyer earlier exercises its Buyout Right pursuant to Section 7.8, its obligation to make Net Sales Payments (but not Milestone Payments) shall terminate as provided in
Section 7.8. 
 4.5 Grant of Security Interest. The Buyer’s obligations to make the Milestone Payments and the Net Sales
Payments shall be secured by a security interest in the RP101 Assets as of the Effective Date, which shall include, for the avoidance of doubt, the License Agreement as amended from time to time on and after the Effective Date (the
“Collateral”), as set forth in the form of Security Agreement attached hereto as Exhibit 4.5 hereto (the “Security Agreement”). For the avoidance of doubt, the Collateral shall not be deemed to include any
other property, assets or rights of Buyer or any third parties. 
 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES OF SELLER 
 Except as set forth in the Disclosure
Schedule attached hereto, each of Resistys, AOI and Avantogen represent and warrant to Buyer with respect to itself as follows: 
 5.1
Organization and Authority. Resistys is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware with full corporate power and authority to execute and consummate this Agreement and such
other instruments, agreements and transactions as may be contemplated hereunder. AOI is a corporation duly organized, validly existing and in good standing under the laws of the state of Nevada with full corporate power and authority to execute and
consummate this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder. Avantogen is a corporation duly organized, validly existing and in good standing under the laws of Australia with full corporate
power and authority to execute and consummate this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder. 
  

 CONFIDENTIAL TREATMENT 

 All corporate acts and other proceedings required to be taken by or on the part of Seller to authorize it to execute,
deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken. This Agreement has been duly executed and delivered by Seller and constitutes the legal,
valid and binding obligations of such party enforceable in accordance with its terms. 
 5.2 Subsidiaries. Resistys represents and
warrants that it does not own directly or indirectly any interest or investment (whether equity or debt) in any corporation, partnership, joint venture, business, trust or other entity. AOI represents and warrants that Seller is a wholly-owned
subsidiary of AOI. 
 5.3 Indebtedness. Schedule 5.3 of the Disclosure Schedules contains a complete, true, and correct
description of (a) the amount of all Liabilities of Resistys and AOI and (b) the basis and holders thereof (individually and collectively, the “Creditors”). Resistys and AOI have not entered into this Agreement with the
intent to hinder, delay or defraud any Creditor or any other person to which Resistys or AOI was, is or may become indebted. Resistys or AOI have engaged in the transactions contemplated by this Agreement on an arm’s-length basis with Buyer.
For its own part, each of Resistys or AOI has conducted such transactions in a manner intended to obtain the highest and best price for the RP101 Assets and to ensure that the amount of the Purchase Price represents at least the fair value of, and
fair consideration in exchange for, the RP101 Assets. 
 5.4 No Violation or Conflict. The execution and delivery by Seller of this
Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and the consummation by Seller of the transactions contemplated hereby and thereunder will not (a) to Seller’s knowledge, violate any law,
statute, rule or regulation or judgment, order, writ, injunction or decree of any court, administrative agency or governmental body, or (b) conflict with, result in any breach of, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under the Certificate of Incorporation or By-Laws (or equivalent governing documents) of Seller or, to Seller’s knowledge, any agreement to which Seller is a party. 
 5.5 Consents and Approvals. Except as set forth on Schedule 5.5 of the Disclosure Schedule, no notice to, declaration, filing or
registration with, or authorization, consent or approval of, or permit from, any domestic or foreign governmental or regulatory body 
  

 CONFIDENTIAL TREATMENT 

 or authority, or any other person or entity, is required to be made or obtained by Seller in connection with the
execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby. All approvals of the Board of Directors (or equivalent) and shareholders of each Seller necessary to authorize the execution and
performance of this Agreement have been obtained by Seller. 
 5.6 Title to RP101 Assets. Seller has good and marketable title to all
the RP101 Assets, and Seller shall convey good and marketable title to the RP101 Assets at Closing, free and clear of any and all liens, encumbrances, charges, claims, restrictions, pledges, security interests, or impositions of any kind, including
those of secured parties. Except as set forth on Schedule 5.6 of the Disclosure Schedule, (a) Seller beneficially owns all of the right, title or other interests to be transferred to Buyer hereunder with respect to all the RP101 Assets,
and (b) none of the RP101 Assets is leased, rented, licensed, or otherwise not owned by Seller. 
 5.7 Rights with Respect to
Intellectual Property. 
 (a) Seller IP Rights. Schedule 2.1(b) hereto sets forth all of the Seller IP Rights. Seller has
the right to convey to Buyer the Seller IP Rights as contemplated hereby. Except as set forth on Schedule 5.7(a) of the Disclosure Schedule, (a) the Seller IP Rights do not, to the knowledge of Seller, infringe any patent or other
intellectual property right of any third party; (b) there are no claims, demands, or proceedings instituted pending or, to the knowledge of Seller, threatened by any party pertaining to or challenging any of Seller’s rights in the Seller
IP Rights; and (c) Seller is not aware of any facts which would render any of the Seller IP Rights invalid or unenforceable. The Seller IP Rights were invented, reduced to practice, produced, developed and/or prepared, as applicable, solely by
employees or independent contractors of Seller, as applicable, in the course of their employment or engagement, and no other party invented or contributed to such intellectual property in any way. Seller has taken all steps reasonably necessary to
maintain its rights in the Seller IP Rights, including normal and customary protections of confidential information. 
 (b) RESprotect
IP. Without having made any independent investigation, Seller is not aware of any facts that would make Licensor’s representations in the second, third, seventh and ninth sentences of Section 6.2.1 of the License Agreement untrue.
Seller has taken all steps reasonably necessary to maintain its rights in the RESprotect Patents or the RESprotect Know-How, including normal and customary protections of confidential information. 
  

 CONFIDENTIAL TREATMENT 

 5.8 Assumed Agreements. Each of the Assumed Agreements to which Seller is a party is valid,
binding and in full force and effect. Seller is not in default under any of the Assumed Agreements, nor to Seller’s knowledge is any other party in default under such agreements, nor is any such default pending or threatened. Other than the
Assumed Agreements, Seller is not a party to any agreements of any kind whatsoever, whether written or oral, concerning or in any way related to the RP101 Program or the RP101 Assets. 
 5.9 Violations of Law. The utilization of the RP101 Assets and the conduct of the RP101 Program by Resistys and AOI (a) does not, to the
knowledge of Resistys and AOI, violate any law, governmental specification, authorization, requirement or any decree, judgment, order or similar restriction in any material respect; and (b) to the knowledge of Resistys and AOI, has not, in any
material respect, been the subject of any investigation or inquiry by any governmental agency or authority regarding violations or alleged violations or, in any material respect been found by any such agency or authority to be in violation of any
law. 
 5.10 Litigation. Neither the RP101 Assets nor the RP101 Program is the subject of (a) any outstanding judgment, order,
writ, injunction or decree of any court, arbitrator or administrative or governmental authority or agency limiting, restricting or affecting the RP101 Assets or the RP101 Program in any material aspect; (b) any pending, or to the knowledge of
Seller, threatened, lawsuit, claim, proceeding, written charge, inquiry, investigation or action of any kind. There are no written claims, actions, suits, proceedings, or investigations pending or, to the knowledge of Seller, threatened, against
Seller with respect to the transactions contemplated in this Agreement. 
 5.11 Taxes. There are no liens for Taxes accrued upon the
RP101 Assets prior to the Closing except for current Taxes not yet due and payable. Resistys has prepared and timely filed all returns, estimates, information statements and reports required to be filed by Resistys with any taxing authority
(“Returns”) that Resistys was required to file prior to the date hereof and such Returns were true and correct in all material respects and were completed in accordance with applicable law. Resistys has paid all Taxes shown to be
payable on all Returns required to have been filed and has withheld all taxes required to have been withheld and, to the extent required, has properly paid such Taxes to the appropriate taxing authority. 
  

 CONFIDENTIAL TREATMENT 

 5.12 Disclosure. No representation or warranty by Seller in this Agreement or any schedule or
exhibit hereto, or any statement, list or certificate furnished by Seller pursuant hereto, contains or will contain any untrue statement of a material fact, or omits or will omit to state a material fact required to be stated therein or necessary to
make the statements contained therein not misleading or necessary in order to provide a prospective purchaser of the RP101 Assets with proper information related to such assets and RP101 Program. Resistys and AOI have disclosed all material adverse
facts of which they have knowledge relating to the RP101 Assets, the RP101 Program and the consummation of the transactions contemplated by this Agreement. 
 ARTICLE 6 
 REPRESENTATIONS AND WARRANTIES OF BUYER 
 Buyer hereby represents and warrants to Seller as follows: 
 6.1 Organization and Authority. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Buyer has full corporate power and authority to execute and
deliver this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, and to perform its obligations hereunder and thereunder. All corporate acts and other proceedings required to be taken by or on the part
of Buyer to authorize Buyer to execute, deliver and perform this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder, have been duly and properly taken. This Agreement has been duly executed and
delivered by Buyer and constitutes the legal, valid and binding obligation of Buyer enforceable in accordance with its terms. 
 6.2 No
Conflict or Violation. The execution and delivery by Buyer of this Agreement and such other instruments, agreements and transactions as may be contemplated hereunder and the consummation by Buyer of the transactions contemplated hereby and
thereunder will not (a) to Buyer’s knowledge, violate any law, statute, rule or regulation or judgment, order, writ, injunction or decree of any court, administrative agency or governmental body, or (b) conflict with, result in any
breach of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under the Certificate of Incorporation or By-Laws of Buyer or, to Buyer’s knowledge, any agreement to which Buyer is a party.

  

 CONFIDENTIAL TREATMENT 

 6.3 Consents and Approvals. No notice to, declaration, filing or registration with, or
authorization, consent or approval of, or permit from, any domestic or foreign governmental or regulatory body or authority, or any other person or entity, is required to be made or obtained by Buyer in connection with the execution, delivery and
performance of this Agreement and the consummation of the transactions contemplated hereby. 
 ARTICLE 7 
 CLOSING; FURTHER ASSURANCES; 
 POST
CLOSING COVENANTS; BUYOUT 
 7.1 Closing. Subject to the terms and conditions of this Agreement, the purchase and sale of the
RP101 Assets pursuant to the terms and conditions hereof (the “Closing”) shall take place on the Effective Date at the offices of DLA Piper US LLP, 153 Townsend, Suite 800, San Francisco, CA 94107, counsel to Buyer, or at such other
time, date and place as mutually agreed upon by the parties. 
 7.2 Escrow Agreement and Purchase Price. At the Closing: 

(a) Buyer, Seller and Escrow Agent shall enter into the Escrow Agreement as provided in Section 4.1; 
 (b) Buyer and Seller shall deliver the list of Creditors set forth on Schedule 5.3 of the Disclosure Schedule to Escrow Agent; and 
 (c) Buyer shall deliver to the Escrow Agent the Purchase Price as set forth in Section 4.1. 
 7.3 Asset Transfer and Assumption Agreements. At the Closing, Seller shall deliver to Buyer such Asset Transfer and Assumption Agreements in form
and substance reasonably satisfactory to Buyer, as shall be effective to vest in Buyer all right, title and interest of Seller in and to the RP101 Assets. 
 7.4 Other Closing Deliverables. At the Closing, the parties shall deliver the following: 
 (a) Seller
shall deliver to Buyer documentation acceptable to Buyer demonstrating that their respective signatories to this Agreement are duly authorized to execute the Agreement on their behalf. 
  

 CONFIDENTIAL TREATMENT 

 (b) Seller shall deliver to Buyer an Assignment and Amendment No. 1 to the PRA Agreement dated as of
the Effective Date among PRA, AOI and Buyer (the “PRA Assignment”), in form and substance satisfactory to Buyer, duly executed by AOI and PRA. 
 (c) Seller shall deliver to Buyer an Assignment of that certain Services Agreement dated October 18, 2004 between Resistys and [****], as amended by COS#1 dated December 6, 2005 and COS#2 dated
April 12, 2007 (the “[****] Assignment”), in form and substance satisfactory to Buyer. 
 (d) Seller shall
deliver to Buyer the Licensor’s consent in writing to the assignment of the License Agreement and the Supply Agreement contemplated hereby, in form and substance satisfactory to Buyer. 
 (e) Seller shall deliver to Buyer all other consents and approvals required of third parties with respect to the transactions contemplated in this
Agreement, in form and substance satisfactory to Buyer, including copies of the approvals of the Boards of Directors of each Seller and of the approval of the shareholders of Resistys and AOI certified by the Secretary of each Seller. 
 (f) AOI shall deliver to Buyer such documents and instruments as are necessary or desirable to transfer the sponsorship of the RP101 IND to Buyer, in
form and substance satisfactory to Buyer. 
 (g) Seller shall deliver to Buyer physical copies of the Assumed Agreements, Seller IP Rights,
Regulatory Filings, Manufacturing Information and Research and Development Materials and all Books and Records related thereto. 
 (h) AOI
shall deliver to Buyer evidence of the conversion of at least 75% of the debt owed by AOI to Chopin Opus One, L.P. into equity of AOI, in form and substance reasonably satisfactory to Buyer. For the avoidance of doubt, the balance of said debt shall
be included in the list of Creditors set forth in Schedule 5.3 of the Disclosure Schedule and shall be paid by the Escrow Agent within thirty (30) days after Closing pursuant to Section 4.1 unless theretofore converted. 

 

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 (i) Buyer shall pay the Licensor the RESprotect Invoices in the amount of Three Hundred Sixty-Five
Thousand Four Hundred Seventy-Four United States Dollars (US$365,474). 
 (j) Buyer shall deliver to Seller appropriate documentation (in
form and substance reasonably satisfactory to Seller) demonstrating that the signatory to this Agreement is duly authorized to execute the Agreement on behalf of Buyer. 
 (k) Buyer shall deliver to Seller copies of the approval of its Board of Directors certified by the Secretary of Buyer. 
 (l) Buyer shall deliver to Seller an executed Security Agreement as set forth in Section 4.5. 
 (m)
Buyer shall deliver to Seller the PRA Assignment and the [****] Assignment, duly executed by Buyer. 
 7.5 Further Assurances;
Power of Attorney. From time to time after the Closing, at the request of Buyer and for no further consideration, Seller shall execute, acknowledge and deliver such assignments, transfers, consents and other documents and instruments and take
such other actions as may be reasonably necessary or desirable to consummate the transactions contemplated hereby, or to effectuate any action contemplated under this Agreement (individually and collectively, the “Further
Assurances”). Each of Resistys, AOI and Avantogen hereby irrevocably makes, constitutes and appoints Buyer, and any officers, employees or agents of Buyer designated by Buyer, with full power of substitution, as its agent and
attorney-in-fact with full power and authority in its place, name and stead, or in Buyer’s name, to execute, acknowledge and deliver such assignments, transfers, consents and other documents and instruments and take such other actions as may be
reasonably necessary or desirable to consummate the transactions contemplated hereby, or to effectuate any action contemplated under this Agreement, with the same legal force and effect as if executed by it (the “Power of
Attorney”), provided that Buyer may only exercise the Power of Attorney if Resistys, AOI and/or Avantogen, as applicable, fail for any reason (including due to its dissolution or liquidation) to perform the Further Assurances

  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 within thirty (30) days of Buyer’s written request describing the Further Assurances requested to be performed.
The Power of Attorney is coupled with an interest and shall be irrevocable. Each of Resistys, AOI and Avantogen hereby ratify and confirm all actions Buyer lawfully does or causes to be done pursuant to the Power of Attorney. Each of Resistys, AOI
and Avantogen hereby agree that third parties may rely upon the representations of Buyer, and any officers, employees or agents of Buyer designated by Buyer, as to any and all matters with respect to any power granted by the Power of Attorney, and
no person or entity who shall act in reliance upon such representations or the authority granted by the Power of Attorney shall incur any liability to Resistys, AOI or Avantogen as a result of such reliance. The powers conferred on Buyer by the
Power of Attorney are solely to protect Buyer’s interests herein and do not impose any duty upon it to exercise any such powers. 
 7.6
Access to Books and Records After Closing. Seller will permit Buyer and its duly authorized representatives access during normal business hours (upon 24 hours written notice to Seller) to all Books and Records in the possession or control of
Seller to the extent that such books and records were not delivered to Buyer. 
 7.7 Buyout of Net Sales Payments. During the Buyout
Period (as defined below), Buyer shall have the right (the “Buyout Right”) to buy out its obligation to pay Resistys the Net Sales Payments pursuant to Section 4.3, on the terms and conditions set forth in this
Section 7.8. For the avoidance of doubt, if Buyer exercises the Buyout Right in accordance with this Section 7.8, its obligation to make any Net Sales Payments to Resistys that would otherwise have been due and payable under
Section 4.2 after the date of the Buyout Notice shall terminate upon the payment to Resistys of the applicable Buyout Consideration (as defined below). For the avoidance of doubt, the exercise of the Buyout Right by Buyer shall not relieve
Buyer of its obligation to pay the Milestone Payments to Resistys pursuant to Section 4.2. 
 (a) Buyout Period. The Buyout Right
shall be exercisable by Buyer during the following periods (each, a “Buyout Period”): 
  

 CONFIDENTIAL TREATMENT 

 (i) During the period commencing on [****] (the “First Buyout Period”). For
purposes of this paragraph, (a) “completion of the Phase II Clinical Trial” shall be deemed to have occurred [****], and (b) “commencement of the Phase III Clinical Trial” shall be deemed to have occurred
[****]; or 
 (ii) [****]. 
 (b) Buyout Consideration. The consideration payable to Resistys for the Buyout Right shall be: 
 (i) during the First Buyout
Period, [****], payable at Buyer’s option in cash or Common Stock (the “Buyout Consideration”); or, 
 (ii)
during the Second Buyout Period, [****], payable at Buyer’s option in cash or Common Stock (also, “Buyout Consideration”). 
 (c) Exercise of Buyout Right. The Buyer may exercise the Buyout Right during the applicable Buyout Period by delivering to Resistys a notice (the “Buyout Notice”) specifying a date (the
“Buyout Date”) not less than thirty (30) days after the date of the Buyout Notice on which the closing of the Buyout Right will occur and whether the Buyout Consideration will be in the form of cash or Common Stock. 

(d) Calculation of Buyout Consideration in the Form of Common Stock. If Buyer elects to pay the Buyout Consideration in Common Stock, the
number of shares of Common Stock comprising the Buyout Consideration shall be determined by dividing the dollar value of the applicable Buyout Consideration by the average closing sales price of the Common Stock as traded on The Nasdaq Stock Market
(or such other securities exchange on which the Common Stock is traded) and reported in The Wall Street Journal for the forty (40) consecutive market trading days on which the Common Stock is traded ending on the date of the Buyout Notice, or
the last market trading day prior to the date of the Buyout Notice, if the date of the Buyout Notice is not itself a market trading day, and rounding to the nearest whole share. 
 (e) Procedure for Payment of Buyout Consideration; Registered Stock. On the Buyout Date, Buyer shall deliver the Buyout Consideration to Resistys.
If Buyer elects to pay the Buyout Consideration in cash, Buyer shall pay the Buyout Consideration by 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 wire transfer in immediately available funds to such account as Resistys shall have designated to Buyer in writing. If
Buyer elects to issue Common Stock in payment of the Buyout Consideration, Buyer shall issue or cause to be issued the number of shares of Common Stock comprising the Buyout Consideration in the name of Resistys, which stock shall be registered at
the time of issuance under the Securities Act. If Buyer issues Common Stock, each of Buyer and Seller shall cooperate in a reasonable manner to provide all information required in connection with the registration of such Common Stock. 
 7.8 Confidentiality. On and after the Effective Date, Seller shall keep secret and retain in strictest confidence, shall not use for the benefit
of themselves or others and shall not disclose to any third party, except with Buyer’s prior written consent, any Confidential Information related to the RP101 Assets or the RP101 Program or any Confidential Information provided by Buyer after
the Effective Date, including any information provided in connection with Section 4.4. 
 7.9 Publicity. The parties agree that
each party may make a public announcement of the execution of this Agreement, provided that the text of any such announcement shall be subject to the approval of the other parties, such approval not to be unreasonably withheld. Any other
publication, news release or other public announcement relating to this Agreement shall first be reviewed and approved by Buyer, AOI and Avantogen, such approval not to be unreasonably withheld unless such publication, news release or other public
announcement contains information previously approved for release hereunder. Notwithstanding the foregoing, any disclosure that is required by applicable law, or by the rules of a nationally recognized securities exchange, as advised by the
disclosing party’s counsel, may be made without the consent of the other parties, although the other parties shall be given prompt written notice of such legally required disclosure and to the extent practicable shall have a reasonable
opportunity to comment on the proposed disclosure. 
 7.10 Operation of Resistys following Closing. Resistys and AOI agree that
Resistys shall have no business or operations following the Closing other than the ownership of its rights under this Agreement, and shall not acquire assets or incur obligations or liabilities of any kind, other than directly pursuant to this
Agreement and the transactions contemplated hereby. 
  

 CONFIDENTIAL TREATMENT 

 ARTICLE 8 
 LIABILITY AND INDEMNIFICATION 
 8.1 Buyer Liabilities. Buyer, and not Seller, shall be liable
for any and all Assumed Liabilities and all Liabilities that arise in connection with the RP101 Assets and/or Buyer’s conduct of the RP101 Program after the date hereof, but only to the extent such Liabilities are caused or are alleged to have
been caused by an act or omission occurring after the date hereof (the “Buyer Liabilities”). Buyer’s Liabilities shall be understood to include all Assumed Liabilities and all Liabilities which accrue after the date hereof
under the Assumed Agreements. 
 8.2 Seller Liabilities. Seller, and not Buyer, shall be liable for any and all Liabilities that arise
in connection with the RP101 Assets and/or the conduct of the RP101 Program on or prior to the date hereof (the “Seller Liabilities”). The Seller Liabilities shall be understood to include all Liabilities which accrued on or prior
to the date hereof under the Assumed Agreements. 
 8.3 Indemnification by Buyer. Buyer indemnifies and holds harmless Seller and
their respective Affiliates and their respective directors, officers, employees, controlling persons, agents and representatives (the “Seller Indemnitees”) from and against (a) the Buyer Liabilities, including any and all
claims by third parties arising out of the conduct after the Closing of the RP101 Program or use or ownership of the RP101 Assets after the Closing; and (b) any and all Liabilities which Seller may incur or suffer which arise out of
(i) Buyer’s breach of any representation, warranty, covenant or agreement made by Buyer in this Agreement; or (ii) any and all actions, suits, proceedings, demands, assessments, judgments, reasonable costs and expenses incident to any
of the foregoing. Notwithstanding that a claim with respect to indemnified Liabilities falls into multiple categories of this Section 8.3, Buyer shall only be required to indemnify a Seller Indemnitee up to the amount of the Liability incurred
or suffered. 
 8.4 Indemnification by Seller. Seller jointly and severally indemnify and hold harmless Buyer, its Affiliates and
their respective directors, officers, employees, controlling persons, agents and representatives (the “Buyer Indemnitees”) from and against (a) the Seller Liabilities, including any and all claims by third parties arising out
of the conduct, on or prior to the Closing, of the RP101 Program or use or ownership of any of the RP101 Assets on or prior to the Closing; and (b) any and all Liabilities which Buyer may incur or suffer which arise out of
(i) Seller’s breach of any representation, warranty, covenant or agreement made by Seller in 
  

 CONFIDENTIAL TREATMENT 

 this Agreement; or (ii) any and all actions, suits, proceedings, demands, assessments, judgments, reasonable costs
and expenses incident to any of the foregoing. Notwithstanding that a claim with respect to indemnified Liabilities falls into multiple categories of this Section 8.4, Seller shall only be required to indemnify up to the amount of the Liability
incurred or suffered. 
 8.5 Claims. Any Buyer Indemnitee or Seller Indemnitee claiming it may be entitled to indemnification under
this Article 8 (the “Indemnified Party”) shall give prompt notice to the other Party (the “Indemnifying Party”) of each matter, action, cause of action, claim, demand, fact or other circumstances upon which a
claim for indemnification (a “Claim”) under this Article 8 may be based. Such notice shall contain, with respect to each Claim, such facts and information as are then reasonably available, and the specific basis for
indemnification hereunder. Failure to give prompt notice of a claim hereunder shall not affect the Indemnifying Party’s obligations under this Section, except to the extent the Indemnifying Party is prejudiced by such failure. 
 8.6 Defense of Actions. The Indemnified Party shall permit the Indemnifying Party, at the Indemnifying Party’s option and expense, to assume
the complete defense of any Claim based on any action, suit, proceeding, claim, demand or assessment by any third party with full authority to conduct such defense and to settle or otherwise dispose of the same and the Indemnified Party will fully
cooperate in such defense; provided the Indemnifying Party will not, in defense of any such action, suit, proceeding, claim, demand or assessment, except with the consent of the Indemnified Party (which consent will not be unreasonably withheld),
consent to the entry of any judgment or enter into any settlement which provides for any relief other than the payment by the Indemnifying Party of monetary damages and which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to the Indemnified Party of a release from all liability in respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such action, suit, proceeding, claim, demand
or assessment, the Indemnifying Party shall be liable to the Indemnified Party for such legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof at the request of the Indemnifying Party. As to
those actions, suits, proceedings, claims, demands or assessments with respect to which the Indemnifying Party does not elect to assume control of the defense, the Indemnified Party will afford the 
  

 CONFIDENTIAL TREATMENT 

 Indemnifying Party an opportunity to participate in such defense, at its cost and expense, and will consult with the
Indemnifying Party prior to settling or otherwise disposing of any of the same. Notwithstanding anything to the contrary herein, with respect to any Claim asserted by a governmental entity relating to Taxes, the Indemnifying Party shall be entitled
to participate in the defense, but the Indemnified Party shall control such defense. The Indemnified Party will not settle any such Claim without the prior consent of the Indemnifying Party, such consent not to be unreasonably withheld. 

8.7 Remedies Cumulative. The remedies provided in this Agreement shall be cumulative and shall not preclude any party from asserting any other
right, or seeking any other remedies, against the other party. 
 8.8 Survival of Representations and Warranties. The representations
and warranties of the parties set forth in this Agreement shall survive the Closing. All Claims under this Article 8 shall expire on the third anniversary of the Effective Date. Notwithstanding the foregoing, termination of such Claims and of the
parties’ obligations hereunder shall not terminate or affect obligations in respect of claims for indemnity or otherwise for which written notice shall have been given by the Identified Party prior to expiration date. 
 8.9 Limitations. The indemnification obligations hereunder shall be limited to the amount of the Purchase Price and the Milestone Payments. In no
event shall either party be entitled to indirect, special, consequential or punitive damages. 
 ARTICLE 9 
 MISCELLANEOUS 
 9.1 Governing
Law. This Agreement shall be deemed to have been made in the State of California and its form, execution, validity, construction and effect shall be governed and construed in accordance with the laws of the State of California, without giving
effect to the principles of conflicts of law thereof. 
 9.2 Jurisdiction. The parties consent to the exclusive jurisdiction of the
state and federal courts within the state of California with respect to any dispute arising out of this Agreement. 
 9.3 Headings.
All section headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 
  

 CONFIDENTIAL TREATMENT 

 9.4 Entire Agreement. This Agreement and the schedules and exhibits hereto are intended to define
the full extent of the legally enforceable undertakings and representations of the parties hereto, and no promise or representation, written or oral, which is not set forth explicitly in such Agreement is intended by either party to be legally
binding. Each of the parties acknowledge that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has relied upon any statements or representations, written or oral, other than those explicitly
set forth herein. 
 9.5 Amendment. This Agreement may not be amended, supplemented or otherwise modified except by an instrument in
writing signed by the parties hereto that specifically refers to this Agreement. 
 9.6 Notices. All notices and other communications
required to be given under this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) five (5) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid, or (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the
following respective addresses (or to such other address as may be specified by notice from time to time by the relevant party): 
  

			
	If to Resistys:	  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: Christopher Nowers

		
	with a copy to:	  	 Michael Hirschberg, Esq.
 Katten Muchin Rosenman LLP

 575 Madison Avenue
 New York, New York
10022-2585

		
	If to AOI:	  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: Christopher Nowers

		
	with a copy to:	  	 Michael Hirschberg, Esq.
 Katten Muchin Rosenman LLP

 575 Madison Avenue
 New York, New York
10022-2585

  

 CONFIDENTIAL TREATMENT 

			
	If to Avantogen:	  	 2121 Avenue of the Stars
 Suite 2550
 Los Angeles, California 90067
 Attn: William Ardrey

		
	If to Buyer:	  	 901 Mariners Island Blvd.
 San Mateo, California 94404

 Attn: Friedhelm Blobel, Chief Executive Officer

		
	with a copy to:	  	 J. Howard Clowes, Esq.
 DLA Piper US LLP
 153 Townsend Street, Suite 800
 San Francisco, CA 94107

 9.7 Assignment. This Agreement and the rights and obligations hereunder shall be binding
upon and inure to the benefit of the parties hereto, their respective successors and permitted assigns. Unless consent in writing is first obtained from the other parties hereto, this Agreement and the rights granted hereunder shall not be
assignable by any party hereto, and any attempted assignment without such consent shall be void. Notwithstanding the foregoing, Buyer may transfer or assign its rights and obligations under this Agreement to (a) an Affiliate, or (b) a
successor to all or substantially all of its business or assets relating to this Agreement whether by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise, provided that such Affiliate or successor agrees to be
bound by the terms of this Agreement. 
 9.8 No Agency. It is understood and agreed that each party shall have the status of an
independent contractor under this Agreement and that nothing in this Agreement shall be construed as authorization for either party to act as agent for the other. No party shall incur any liability for any act or failure to act by employees of
another party. 
 9.9 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against
either party. 
 9.10 Counterparts. This Agreement may be executed in two counterparts, each of which shall be an original as against
any party whose signature appears thereon but both of which together shall constitute one and the same instrument. A facsimile transmission of the signed Agreement shall be legal and binding on both parties. 
  

 CONFIDENTIAL TREATMENT 

 9.11 Payment of Expenses. All costs and expenses associated with this Agreement and the
transactions contemplated thereby, including the fees of counsel and accountants, shall be borne by the party incurring such expenses. 
 9.12 No Brokers. No broker, finder, agent or similar intermediary has acted for or on behalf of any party hereto or in connection with this Agreement or the transactions contemplated hereby and no broker, finder, agent or
intermediary is entitled to any fee from any party hereto in connection with this Agreement or the transactions contemplated hereby. 
 [Signature Page Follows] 
  

 CONFIDENTIAL TREATMENT 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this
Agreement as of the Effective Date. 
  

									
			
	RESISTYS:	  		 	BUYER:
			
	RESISTYS, INC.	  		 	SCICLONE PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Chris Nowers
	  		 	By:	 	 /s/ Friedhelm Blobel

	Name:	 	Chris Nowers	  		 	Name:	 	Friedhelm Blobel
	Title:	 	President	  		 	Title:	 	CEO and President
			
	AVANTOGEN:	  		 	AOI:
			
	AVANTOGEN LIMITED	  		 	AVANTOGEN ONCOLOGY, INC.
					
	By:	 	 /s/ William Ardrey
	  		 	By:	 	 /s/ Angela Bronow Davanzo

	Name:	 	William Ardrey	  		 	Name:	 	Angela Bronow Davanzo
	Title:	 	Chairman of the Board	  		 	Title:	 	Chief Financial Officer

 [Signature Page to Assignment and Purchase Agreement] 
  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 2.1(A) 
 Assumed Agreements 
 1. License Agreement dated August 30, 2004 among Resistys, Inc., Avantogen Limited (formerly,
Australian Cancer Technology Limited) and RESprotect GmbH. 
 2. Supply Agreement for Clinical Trial Material dated September 13, 2004 between Resistys,
Inc. and RESprotect GmbH. 
 3. Agreement for Clinical Trials Management Services (PRA Project ID: [****]) dated August 31, 2006 by and between
Avantogen Oncology, Inc. and Pharmaceutical Research Associates, Inc., as amended by the PRA Assignment. 
 4. Services Agreement dated October 18, 2004
between Resistys, Inc. and [****], as amended by COS#1 dated December 6, 2005 and COS#2 dated April 12, 2007. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 2.1(B) 
 Seller IP Rights 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 2.1(C) 
 Regulatory Filings 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 2.1(D) 
 Manufacturing Information 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 2.1(E) 
 Research and Development Materials 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 EXHIBIT 4.1 
 Form of Escrow Agreement 
 ESCROW AGREEMENT, dated this 25th day of April, 2007 (this
“Agreement”), by and among SCICLONE PHARMACEUTICALS, INC. (“SciClone”), RESISTYS, INC. (“Resistys”), AVANTOGEN LIMITED, (“Avantogen”), AVANTOGEN ONCOLOGY, INC. (“AOI”) and KATTEN MUCHIN ROSENMAN LLP
(the “Escrow Agent”). 
 WHEREAS, Resistys, Avantogen and AOI are selling certain assets to SciClone pursuant to that certain
Assignment and Purchase Agreement of even date herewith by and among Resistys, Avantogen, AOI and SciClone (the “Purchase Agreement”) in consideration for which SciClone will pay Resistys, among other things, the cash amount of
$1,516,648.89 (the “Initial Cash Payment”) at the closing of the transactions contemplated by the Purchase Agreement (the “Closing”). 
 WHEREAS, the parties have agreed that the Initial Cash Payment will be deposited in escrow at the Closing for direct payment to certain creditors of Resistys and AOI; and 
 WHEREAS, the parties propose to establish an escrow account with the Escrow Agent pursuant to the terms and conditions of this Agreement. 
 NOW THEREFORE, it is agreed as follows: 
 1.
Establishment of Escrow. The Escrow Agent hereby agrees to receive and disburse the Initial Cash Payment in accordance herewith. 
 2.
Deposit of Escrowed Property. Upon the Closing, SciClone shall deliver the Initial Cash Payment to the Escrow Agent by wire transfer to the Escrow Agent in immediately available funds. Upon receipt of the Initial Cash Payment from SciClone,
the Escrow Agent shall credit such funds (the “Escrow Funds”) to an interest-bearing account (the “Escrow Account”) held by the Escrow Agent. 
 3. List of Creditors. At the Closing, Resistys, AOI and SciClone shall furnish to the Escrow Agent the list of creditors of Resistys and AOI attached to the Purchase Agreement, which list shall be attached
hereto as Schedule A. 
 4. Disbursements from the Escrow Account. Promptly after the Closing, but in no event later than five
(5) days after the Closing, the Escrow Agent shall disburse from the Escrow Account the amounts listed on Schedule A to the creditors listed on such schedule, other than RESprotect GmbH and Pharmaceutical Research Associates, Inc., who shall be
paid $49,761.48 and $113,589.63, respectively, by Buyer on behalf of Seller pursuant to Section 4.1 of the Purchase Agreement. The Escrow Agent shall hold the balance of the Escrow Funds for a period of thirty (30) days after the Closing
(the “Escrow Period”). During the Escrow Period, upon receipt of joint written instructions from the other parties to this Agreement, the Escrow Agent shall disburse additional amounts 
  

 CONFIDENTIAL TREATMENT 

 from the Escrow Account to discharge claims of other creditors of Resistys and AOI or additional claims of the creditors
listed on Schedule A. During the Escrow Period, Escrow Agent shall notify Resistys, AOI, Avantogen and SciClone if it receives any claims from creditors of Resistys and AOI not listed on Schedule A or additional claims from the creditors listed on
Schedule A. Upon the expiration of the Escrow Period, the Escrow Agent shall disburse to Resistys the remaining balance of the Escrow Funds, less any amounts equal to any pending unresolved creditor claims. The Escrow Agent shall continue to hold
the Escrow Funds with respect to pending unresolved creditor claims in the Escrow Account after the expiration of the Escrow Period and disburse such funds only upon receipt of joint written instructions from the other parties to this Agreement.

 5. Concerning the Escrow Agent. To induce the Escrow Agent to act hereunder, it is further agreed by SciClone, Resistys, Avantogen
and AOI that: 
 (a) The Escrow Agent shall not be under any duty to give the Escrow Funds held by it hereunder any greater degree of care
than it gives its own similar property and shall not be required to invest any funds held hereunder except as may be otherwise directed in this Agreement. Uninvested funds held hereunder shall not earn or accrue interest. 
 (b) This Agreement expressly sets forth all the duties of the Escrow Agent with respect to any and all matters pertinent hereto. No implied duties or
obligations shall be read into this Agreement against the Escrow Agent. The Escrow Agent shall not be bound by the provisions of any agreement among the other parties hereto except this Agreement. 
 (c) The Escrow Agent shall not be liable for any action taken or omitted by it in good faith unless a court of competent jurisdiction determines that the
Escrow Agent’s willful misconduct was the primary cause of any loss to the other parties to this Agreement. The Escrow Agent may consult with counsel of its own choice and shall have full and complete authorization and protection for any action
taken or omitted by it hereunder in good faith and in accordance with the opinion of such counsel. 
 (d) The Escrow Agent shall be entitled
to rely upon any order, judgment, certification, demand, notice, instrument or other writing delivered to it hereunder without being required to determine the authenticity or the correctness of any fact stated therein or the propriety or validity of
the service thereof. The Escrow Agent may act in reliance upon any instrument or signature believed by it in good faith to be genuine and may assume, if in good faith, that any person purporting to give notice or receipt or advice or make any
statement or execute and document in connection with the provisions hereof has been duly authorized to do so. 
 (e) SciClone, on the one
hand, and Resistys, Avantogen and AOI, on the other hand, jointly agree to indemnify the Escrow Agent for, and to hold it harmless against, any loss, liability or expense arising out of or in connection with this Agreement and carrying out its
duties hereunder, including the costs and expenses of defending itself against any claim of liability, except in those cases where the Escrow Agent has been guilty of gross negligence or willful misconduct. Anything in this Agreement to the contrary
notwithstanding, in no event shall the Escrow Agent be liable for special, indirect or consequential loss or damage of any kind 
  

 CONFIDENTIAL TREATMENT 

 whatsoever (including but not limited to lost profits), even if the Escrow Agent has been advised of the likelihood of
such loss or damage and regardless of the form of action. This paragraph (e) and paragraph (c) of this Section 6 shall survive notwithstanding any termination of this Agreement or the resignation of the Escrow Agent. 
 (f) The Escrow Agent does not have any interest in the Escrow Funds deposited hereunder but is serving as escrow holder only. 
 (g) The Escrow Agent makes no representation as to the validity, value, genuineness or the collectibility of any security or other documents or
instruments held by or delivered to it. 
 (h) The Escrow Agent shall not be called upon to advise any party as to the wisdom in selling or
retaining or taking or refraining from any action with respect to any securities or other property deposited hereunder. 
 (i) The Escrow
Agent (and any successor escrow agent) at any time may be discharged from its duties and obligations hereunder by the delivery to it of notice of termination signed jointly by SciClone, Resistys, Avantogen and AOI or at any time may resign by giving
written notice to such effect to SciClone, Resistys, Avantogen and AOI, and, upon any such termination or resignation, the Escrow Agent shall deliver the Escrow Funds to any successor escrow agent designated jointly by SciClone, Resistys, Avantogen
and AOI in writing, or to any court of competent jurisdiction if no such successor escrow agent is designated, whereupon the Escrow Agent shall be discharged of and from any and all further obligations arising in connection with this Agreement. The
termination or resignation of the Escrow Agent shall take effect on the earlier of (i) the appointment of a successor (including a court of competent jurisdiction) or (ii) the day that is thirty (30) days after the date of delivery:
(A) to the Escrow Agent of the joint notice of termination or (B) to SciClone, Resistys, Avantogen and AOI of the Escrow Agent’s written notice of resignation. If at that time the Escrow Agent has not received a designation of a
successor escrow agent, the Escrow Agent’s sole responsibility after that time shall be to keep the Escrow Funds safe until receipt of a designation of successor escrow agent or any enforceable order of a court of competent jurisdiction.

 (j) The Escrow Agent shall have no responsibility for the contents of any writing of any third party contemplated herein as a means to
resolve disputes and may rely without any liability upon the contents thereof. 
 (k) The Escrow Agent shall not incur any liability for
following the instructions herein contained or expressly provided for or written instructions given by the parties hereto. 
 (l) In the
event that the Escrow Agent shall be uncertain as to its duties or rights hereunder or shall receive instructions, claims or demands from any party hereto which, in its opinion, conflict with any of the provisions of this Agreement, it shall be
entitled to refrain from taking any action and its sole obligation shall be to keep safely all property held in escrow until it shall be directed otherwise in writing by all of the other parties hereto or by a final order or judgment of a court of
competent 
  

 CONFIDENTIAL TREATMENT 

 jurisdiction. Additionally, in the event of any disagreement between the parties hereto resulting in adverse claims or
demands being made in connection with the Escrow Funds, the Escrow Agent shall be entitled to retain the Escrow Funds until the Escrow Agent shall have received a final and non-appealable order of a court of competent jurisdiction directing delivery
of the Escrow Funds. Any court order referred to in the preceding sentence shall have been accompanied by a legal opinion of counsel for the presenting party satisfactory to the Escrow Agent to the effect that said court order is final and
non-appealable. The Escrow Agent shall act on such court order and legal opinion without further question. 
 (m) SciClone, on the one hand,
and Resistys, Avantogen and AOI, on the other hand, jointly agree to pay or reimburse the Escrow Agent upon request for all reasonable expenses, disbursements and advances, including reasonable attorney’s fees, incurred or made by it in
connection with the performance of this Agreement. 
 (n) The parties hereto irrevocably (i) submit to the jurisdiction of any New York
State or federal court sitting in New York City in any action or proceeding arising out of or relating to this Agreement, (ii) agree that all claims with respect to such action or proceeding shall be heard and determined in such New York State
or federal court and (iii) waive, to the fullest extent possible, the defense of an inconvenient forum. The parties hereby consent to and grant any such court jurisdiction over the persons of such parties and over the subject matter of any such
dispute and agree that delivery or mailing of process or other papers in connection with any such action or proceeding in the manner provided hereinabove, or in such other manner as may be permitted by law, shall be valid and sufficient service
hereof. 
 (o) The duties and responsibilities of the Escrow Agent hereunder shall be determined solely by the express provisions of this
Agreement, and no other or further duties or responsibilities shall be implied. The Escrow Agent shall not have any liability under, nor duty to inquire into, the terms and provisions of any agreement or instructions, other than as outlined in this
Agreement. 
 (p) The parties acknowledge that the Escrow Agent is acting as counsel to Resistys, Avantogen and AOI in connection with the
Purchase Agreement and the transactions contemplated thereby and shall have the right to continue to act in such capacity notwithstanding its appointment as Escrow Agent hereunder. 
 6. Notices. Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be (i) delivered by
hand, (ii) sent by mail with proper postage prepaid, (iii) sent by reputable overnight express courier, (iv) telecopied or (v) sent by email and addressed as follows: 
 If to SciClone: 
 901 Mariners Island Blvd.

 San Mateo, California 94404 
 Attention: Richard Waldron, Chief Financial Officer 
 Fax No.: (650) 358-3469 
 Email: rwaldron@SCICLONE.com 
  

 CONFIDENTIAL TREATMENT 

 If to Resistys, Avantogen and AOI: 
 2121 Avenue of the Stars, Suite 2550 
 Los
Angeles, California 90067 
 Attention: William Ardrey 
 Fax No.: 
 Email: qmgardrey@aol.com 
 If to the Escrow Agent: 
 Katten Muchin
Rosenman LLP 
 575 Madison Avenue 
 New York, New York 10022 
 Attention: Michael Hirschberg, Esq. 
 Fax No.: (212) 894-5646 
 Email:
michael.hirschberg@kattenlaw.com 
 or to such other address as the person to whom notice is to be given may have previously furnished to the other in the
above-referenced manner. All such notices and communications, if mailed, shall be effective when deposited in the mails, except that notices and communications to the Escrow Agent and notices of changes of address shall not be effective until
received. In the event that the Escrow Agent, in its sole discretion, shall determine that an emergency exists, the Escrow Agent may use such other means of communications as the Escrow Agent deems advisable. 
 7. Miscellaneous. 
 (a) This Agreement
shall be binding upon and inure solely to the benefit of the parties hereto and their respective successors and assigns, heirs, administrators and representatives and shall not be enforceable by or inure to the benefit of any other third party
except as provided in paragraph (i) of Section 5 with respect to the termination of, or resignation by, the Escrow Agent. No party may assign any of its rights or obligations under this Agreement without the written consent of the other
party. 
 (b) This Agreement shall be construed in accordance with and governed by the internal laws of the State of New York (without
reference to its rules as to conflicts of law). 
 (c) This Agreement may only be modified by a writing signed by all of the parties hereto.
No waiver hereunder shall be effective unless in a writing signed by the party to be charged. 
 (d) This Agreement shall terminate upon the
disbursement pursuant to Section 4 of all amounts held in the Escrow Account. 
  

 CONFIDENTIAL TREATMENT 

 (e) The section headings herein are for convenience only and shall not affect the construction thereof.
Unless otherwise indicated, references to Sections are to Sections contained herein. 
 (f) This Agreement may be executed in one or more
counterparts but all such separate counterparts shall constitute but one and the same instrument; provided that, although executed in counterparts, the executed signature pages of each such counterpart may be affixed to a single copy of this
Agreement which shall constitute an original. 
 (g) For purposes of this Agreement, “business day” shall be defined as any day
which is not a Saturday, a Sunday or a day on which banks or trust companies in the City and State of New York are authorized or obligated by law, regulation or executive order to remain closed. 
  

 CONFIDENTIAL TREATMENT 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day and year
first above written. 
  

			
	SCICLONE PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	RESISTYS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	AVANTOGEN LIMITED
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	AVANTOGEN ONCOLOGY, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	KATTEN MUCHIN ROSENMAN LLP
		
	By:	 	 /s/ Michael Hirschberg

	Name:	 	Michael Hirschberg
	Title:	 	Partner

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE A 
  

 CONFIDENTIAL TREATMENT 

 EXHIBIT 4.5 
 Form of Security Agreement 
 THIS SECURITY AGREEMENT (the “Agreement”) is entered into as
of April 25, 2007 (the “Effective Date”) by and between SciClone Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 901 Mariners Island Boulevard, Suite 205, San Mateo, California 94404
(“Buyer”), and Resistys, Inc., a Delaware corporation having a principal place of business at having its principal place of business at 2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067 (“Seller”).

 RECITALS 
 WHEREAS, Buyer and
Seller are parties to that certain Assignment and Purchase Agreement of even date herewith (the “Assignment Agreement”) by and among Buyer, Seller, Avantogen Limited (formerly, Australian Cancer Technology Limited), an Australian
corporation (“Avantogen”), and Avantogen Oncology, Inc., a Nevada corporation (“AOI”), pursuant to which Buyer will purchase from Seller, Avantogen and AOI the RP101 Assets (as that term is defined in the Assignment
Agreement). 
 WHEREAS, pursuant to Section 4.5 of the Assignment Agreement, Buyer has agreed to secure its obligation to make certain
payments to Seller by granting a security interest in the RP101 Assets to Seller, on the terms and conditions of this Agreement. 
 NOW,
THEREFORE, in consideration of the foregoing recitals, the agreements of the parties hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Buyer and Seller hereby agree as
follows: 
 1. Defined Terms. The following capitalized terms shall have the meanings ascribed to them below: 
 a. “Chattel Paper” shall have the meaning ascribed thereto in the Code. 
 b. “Code” shall mean the Uniform Commercial Code as from time to time in effect in the State of Delaware. 
 c. “Collateral” shall have the meaning set forth in section 2 hereof. 
 d. “Contract” shall have the meaning ascribed thereto in the Code. 
 e. “Event of Default” shall mean the failure by Buyer to make (a) a Milestone Payment within thirty (30) days of such payment
becoming due and payable as required by Section 4.4(b) of the Assignment Agreement, or (b) a Net Sales Payment within sixty (60) days of after the close of the applicable quarter as required by Section 4.4(c) of the Assignment
Agreement. 
  

 CONFIDENTIAL TREATMENT 

 f. “Instrument” shall have the meaning ascribed thereto in the Code. 
 g. “Obligations” shall mean the Buyer’s obligations to make (a) the Milestone Payments pursuant to Sections 4.2 and 4.4 of the
Assignment Agreement, and (b) the Net Sales Payments pursuant to Sections 4.3 and 4.4 of the Assignment Agreement, subject to Section 4 below. 
 Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Assignment Agreement. 
 2. Grant of Security Interest. To secure Buyer’s prompt, punctual, and faithful performance in making Milestone Payments and Net Sales Payments pursuant to the Assignment Agreement, Buyer hereby grants to
Seller a security interest in the RP101 Assets as received from Seller on the Effective Date, which shall include, for the avoidance of doubt, that certain License Agreement dated August 30, 2004 among Seller, Avantogen Limited and RESprotect
GmbH, as such agreement may be amended from time to time on and after the Effective Date (the “Collateral”), which Collateral shall not be deemed to include any other property, assets or rights of Buyer or any third parties;
provided, however, that the grant of the foregoing security interest shall not extend to, and the term “Collateral” shall not include, any Contract, Instrument or Chattel Paper in which Buyer has any right, title or interest
if and to the extent such Contract, Instrument or Chattel Paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Buyer therein would be prohibited and would,
in and of itself, cause or result in a default thereunder enabling another person party to such Contract, Instrument or Chattel Paper to enforce any remedy with respect thereto; provided further that the foregoing exclusion shall not
apply if (a) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such Contract, Instrument or Chattel Paper or (b) such prohibition would be rendered ineffective
pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity; provided further that
immediately upon the ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and Buyer shall be deemed to have granted a security interest in, all its rights, title and interests in and to such Contract, Instrument
or Chattel Paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Seller’s security interest in and to all
rights, title and interests of the Collateral in or to any payment obligations or other rights to receive monies due or to become due under any such Contract, Instrument or Chattel Paper and in any such monies and other proceeds of such Contract,
Instrument or Chattel Paper. 
 3. Remedies. If an Event of Default shall occur and be continuing, Seller may exercise, in addition to
all other rights and remedies granted to it this Agreement and in any other instrument or agreement securing, evidencing or relating to the Obligations, all rights and remedies of a secured party under the Code. Without limiting the generality of
the foregoing, Seller, without demand of performance or other demand, presentment, protest, advertisement or notice of any kind (except any notice required by law referred to below) to or upon Buyer or any other person (all and each of which
demands, defenses, advertisements and notices are hereby 
  

 CONFIDENTIAL TREATMENT 

 waived), may in such circumstances forthwith sell, lease, assign, give option or options to purchase, or otherwise
dispose of and deliver the Collateral or any part thereof (or contract to do any of the foregoing), in one or more parcels at public or private sale or sales, at any exchange, broker’s board or office of Seller or elsewhere upon such terms and
conditions as they may deem advisable and at such prices as they may deem best, for cash or on credit or for future delivery without assumption of any credit risk. Seller shall have the right upon any such public sale or sales, and, to the extent
permitted by law, upon any such private sale or sales, to purchase the whole or any part of the Collateral so sold, free of any right or equity of redemption in Buyer, which right or equity is hereby waived or released. Buyer further agrees, at
Seller’s request, to assemble the Collateral and make it available to Seller at places that Seller shall reasonably select, whether at Buyer’s premises or elsewhere. Seller shall apply the net proceeds of any such collection, recovery,
receipt, appropriation, realization or sale, after deducting all reasonable costs and expenses of every kind incurred therein or incidental to the care or safekeeping of any of the Collateral or in any way relating to the Collateral or the rights of
Seller hereunder, including, without limitation, reasonable attorney’s fees and disbursements, to the payment in whole or in part of the Obligations, in such order as Seller may elect, and only after such application and after the payment by
Seller of any other amount required by any provision of law, need Seller account for the surplus, if any, to Buyer. To the extent permitted by applicable law, Buyer waives all claims, damages and demands it may acquire against Seller arising out of
the exercise by Seller of any of their rights hereunder. If any notice of a proposed sale or other disposition of Collateral shall be required by law, such notice shall be deemed reasonable and proper if given at least ten (10) days before such
sale or other disposition. Buyer shall remain liable for any deficiency if the proceeds of any sale or other disposition of the Collateral are insufficient to pay the Obligations and the reasonable fees and disbursements of any attorneys employed by
Seller to collect such deficiency. 
 4. Term of Agreement. This Agreement and the security interest in the Collateral granted by
Buyer to Seller hereunder shall terminate upon the expiration of the Additional Payment Term as provided in Section 4.4(i) of the Assignment Agreement, provided that if Buyer earlier exercises its Buyout Right with respect to the Net
Sales Payments pursuant to Section 7.8 of the Assignment Agreement, the Net Sales Payments shall no longer be included as an Obligation hereunder. Promptly following any such termination, the Seller on their behalf will join in executing any
termination statements and other filings with respect to any financing statement executed and filed pursuant to this Agreement or required for evidencing termination of this Agreement or Seller’s security interest in the Collateral and file any
such termination statements or other filings with the appropriate agencies. 
 5. Notices. All notices, requests, demands and other
communications provided for hereunder shall be as provided under Section 9.6 of the Assignment Agreement. 
 6. Governing Law.
This Agreement shall be deemed to have been made in the State of California and its form, execution, validity, construction and effect shall be governed and construed in accordance with the laws of the State of California, without giving effect to
the principles of conflicts of law thereof. 
  

 CONFIDENTIAL TREATMENT 

 7. Jurisdiction. The parties consent to the exclusive jurisdiction of the state and federal courts
within the state of California with respect to any dispute arising out of this Agreement. 
 8. Headings. All section headings
contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this Agreement. 
 9.
Entire Agreement. This Agreement and the Assignment Agreement are intended to define the full extent of the legally enforceable undertakings and representations of the parties hereto, and no promise or representation, written or oral, which
is not set forth explicitly in such agreements is intended by either party to be legally binding. Each of the parties acknowledge that in deciding to enter into this Agreement and to consummate the transaction contemplated hereby none of them has
relied upon any statements or representations, written or oral, other than those explicitly set forth herein. 
 10. Amendment. This
Agreement may not be amended, supplemented or otherwise modified except by an instrument in writing signed by the parties hereto that specifically refers to this Agreement. 
 11. Assignment. This Agreement and the rights and obligations hereunder shall be binding upon and inure to the benefit of the parties hereto,
their respective successors and permitted assigns. Unless consent in writing is first obtained from the other parties hereto, this Agreement and the rights granted hereunder shall not be assignable by any party hereto, and any attempted assignment
without such consent shall be void. Notwithstanding the foregoing, Buyer may transfer or assign its rights and obligations under this Agreement to (a) an Affiliate, or (b) a successor to all or substantially all of its business or assets
relating to this Agreement whether by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise, provided that such Affiliate or successor agrees to be bound by the terms of this Agreement. 
 12. Counterparts. This Agreement may be executed in two counterparts, each of which shall be an original as against any party whose signature
appears thereon but both of which together shall constitute one and the same instrument. A facsimile transmission of the signed Agreement shall be legal and binding on both parties. 
 [Remainder of Page Intentionally Left Blank] 
  

 CONFIDENTIAL TREATMENT 

 IN WITNESS WHEREOF, the parties, through their authorized officers, have duly executed this Agreement as
of the date first written above. 
  

									
	SELLER:	 		 	BUYER:
			
	RESISTYS, INC.	 		 	SCICLONE PHARMACEUTICALS, INC.
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 5 
 Disclosure Schedules 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

  

 CONFIDENTIAL TREATMENT 

 SCHEDULE 5.3 
 Creditors 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

 SCHEDULE 5.5 
 Consents and Approvals 
 1. Consent of RESprotect GmbH to the assignment to SciClone of that certain (a) License
Agreement dated August 30, 2004 among Resistys, Inc., Avantogen Limited (formerly, Australian Cancer Technology Limited) and RESprotect GmbH, and (b) Supply Agreement for Clinical Trial Material dated September 13, 2004 between
Resistys, Inc. and RESprotect GmbH. 
 2. Consent of Pharmaceutical Research Associates, Inc. to the assignment to SciClone of that certain Agreement
for Clinical Trials Management Services (PRA Project ID: [****]) dated August 31, 2006 by and between Avantogen Oncology, Inc. and Pharmaceutical Research Associates, Inc. 
 3. [****] 
 4. Notice to FDA regarding transfer of RP101 IND sponsorship to
SciClone. 
 5. Approvals of the Boards of Directors of Seller and the Shareholders of Resistys, Inc. and Avantogen Oncology, Inc. 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

 SCHEDULE 5.6 
 Title Exceptions 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

 SCHEDULE 5.7(a) 
 Seller IP Rights Exceptions 
 [****] 
  

	****	Certain information on this page has been omitted and filed separately with the commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]